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ABSTRACT
THE RETINOBLASTOMA PROTEIN MEDIATES METABOLIC
REPROGRAMMING IN LUNG CANCER

Lindsey R. Conroy
January 24, 2020
Lung cancer is among the most frequently diagnosed cancers and is the
leading cause of cancer-related deaths worldwide. One of the hallmark events in
lung cancer pathogenesis is deregulation of the cell cycle. The retinoblastoma
protein (pRb) is a tumor suppressor that is deleted, mutated, or inactivated in most
lung cancer cases. Canonically, pRb functions to regulate cell cycle progression
by repressing the transcriptional activity of the E2F family of transcription factors,
inhibiting S phase entry. Although the cell cycle functions of pRb have been well
established, recent studies have highlighted a functional role for pRb in controlling
cellular metabolism. This body of work describes the role of pRb in mediating
metabolic reprogramming in both in vitro and in vivo models of lung cancer.
To define metabolic pathways regulated by pRb in vitro, I performed several
metabolic assays and stable-isotope labeled metabolomics studies in A549 lung
adenocarcinoma cells. pRb activity was manipulated via treatment with palbociclib,
a CDK4/6 inhibitor which inhibits the phosphorylation and subsequent inactivation
of pRb. Palbociclib decreases nucleotide biosynthesis by reducing activity of
v

glucose 6-phosphate dehydrogenase, the rate limiting enzyme in the pentose
phosphate pathway (PPP), without altering glycolysis. Additionally, palbociclib
increases glutamine dependency for mitochondrial function and sensitizes A549
cells to the glutaminase inhibitor, CB-839. The effects of palbociclib on both the
PPP and glutamine utilization occur in an pRb-dependent manner.
Separately, using a combination of steady-state and stable-isotope labeled
metabolomics, I assessed global changes in metabolism resulting from the loss of
the gene encoding pRb (Rb1) in Kras-driven lung tumors in vivo. Depletion of Rb1
in a mutant Kras-driven mouse model of lung cancer enhances glucose
metabolism, via upregulation of key genes within glycolysis, without altering
mitochondrial pyruvate oxidation. Moreover, pRb-deficient tumors do not exhibit
alterations in glutamine anaplerosis or utilization of alternative nutrient sources
(e.g. circulating lactate) compared to lung tumors with intact pRb.
Together the work described in this dissertation expands our knowledge of
the metabolic phenotype resulting from pRb dysfunction in lung cancer, and
highlights specific metabolic perturbations that may be exploited therapeutically
based on pRb status in patient lung tumors.
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CHAPTER 1: INTRODUCTION
Lung Cancer
Lung cancer is among the most frequently diagnosed cancers and is the
leading cause of cancer-related mortality worldwide, with an estimated 1.6 million
deaths each year (1-3). The overall five-year survival rate for lung cancer patients
is only 18%, with more than half of these patients succumbing to their disease
within the first year of diagnosis (1). The most common risk factor for developing
lung cancer is tobacco smoking, which comprises over 80% of all cases in the
United States as well as other countries with prevalent tobacco use (4). However,
environmental exposures including second-hand smoke, radon, air pollution,
occupational carcinogens, and genetic susceptibility have a role in lung cancer
development (2,5,6). Approximately 85% of patients are diagnosed with having
non-small cell lung cancer (NSCLC), of which lung adenocarcinoma (LUAD) and
lung squamous cell carcinoma (LUSC) are the most common subtypes, while small
cell lung cancer (SCLC) accounts for the remaining 15% of diagnoses (3). Each
subtype has distinct oncogenic drivers, epidemiology, and therapeutic options,
which differentially impact patient outcomes. This dissertation will focus on the
NSCLC subtype as it is accounts for the majority of lung cancer diagnoses.
A NSCLC diagnosis is defined by the TNM staging system, where stage is
categorized by the primary tumor (T), the extent of lymph node involvement (N),
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and distant metastasis (M) (7). Common metastasis sites for NSCLC are the brain,
liver, and bone (8). Often, NSCLC is detected at more advanced-stages, resulting
in a poorer clinical outcome for patients; however, this is beginning to improve with
better screening methods and more efficacious therapies (1,2,4,7). Over the past
two decades, the treatment of lung cancer has changed from the use of nonspecific cytotoxic therapies to targeted or personalized strategies based on the
genetic alterations of the patient’s tumor (5). Among the many cellular processes
genetically altered during lung cancer pathogenesis, the most prevalent involves
disruption of cell cycle control.
The Cell Cycle
The mammalian cell cycle is comprised of five sequential phases: G0, G1,
S, G2, and M. During two of these phases, cells must complete two fundamental
events to ensure proper cell division. First, in S phase, the cell must generate a
single and faithful copy of its genetic material, while in M phase, the cell must
partition all of its cellular compartments into two identical daughter cells. The two
other phases of the cell cycle, G1 and G2, are considered “gap” phases. During
these times, cells prepare themselves for successful entry and completion of the
S and M phases, respectively. In the absence of mitogenic signaling or when cells
cease proliferation, they exit the cell cycle and remain in G0. In this non-dividing
phase, cells are referred to as quiescent, or in a state of cell cycle arrest. Cells in
G0 account for the majority of non-proliferative cells in the human body.
Over the last several decades, extensive research has been conducted on
the regulation of cell cycle in both normal and malignant cells. One of the central
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players of cell cycle progression are the cyclin-dependent kinases (CDKs). The
activity of these serine/threonine kinases is tightly regulated by their ability to form
complexes with larger proteins called cyclins. Transitioning from one cell cycle
phase to the next occurs in an orderly fashion due to the different cyclin-CDK
complexes that form and activate their respective downstream targets during
specific cell cycle phases (9). Timely activation of cyclin-CDK complexes is
controlled by expression of the INK4 and the kinase inhibitory (WAF/KIP) family of
proteins, which inhibit the association of CDKs with cyclins (10). In addition to
cyclin-CDK regulation, there are several cell cycle checkpoints in place that ensure
cells preserve genome integrity and chromosomal stability (11).
G1 to S Phase Transition
Quiescent cells (G0) enter the cell cycle in response to mitogenic or growth
factor signals, resulting in increased intracellular levels of D-type cyclins (D1-3).
Cyclin D then localizes to the nucleus where it forms active Cyclin D-CDK4 or
Cyclin D-CDK6 complexes that phosphorylate the retinoblastoma protein [pRb,
RB1(gene), also referred to as Rb] and other members of the “pocket” protein
family (12,13). The pRb pocket proteins (pRb, p107, and p130) negatively regulate
the transition from G1 to S phase by binding to the E2F family of transcription
factors and repressing the expression of genes required for cellular processes,
including DNA replication (14). Phosphorylation of pRb by Cyclin D-CDK4/6
complexes induces a conformational change that promotes its dissociation from
E2Fs, thereby enabling the transcription of genes required for DNA synthesis and
transition from G1 to S phase (Figure 1) (15). pRb is then hyperphosphorylated

3

Figure 1. Schematic of Rb in cell cycle control. In early G1, Rb physically
associates with E2F transcription factors, blocking their transactivation domain. In
late G1, Rb phosphorylation releases E2Fs, allowing the expression of genes that
encode products necessary for S-phase progression. Rb and p-Rb indicate
unphosphorylated and phosphorylated Rb, respectively (15). Reprinted with
permission from [Springer Nature] : [Nature] [NATURE REVIEWS CANCER]
(Tailoring to RB: tumour suppressor status and therapeutic response, Erik S.
Knudsen and Karen E. Knudsen), [ãMACMILLIAN PUBLISHERS LIMITED]
(2008).
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during the late G1 phase by the cyclin E-CDK2 complex, which reinforces pRb
inactivation and irreversible initiation of the gene expression program of S phase
(11,16). This stage is referred to as the restriction point. Alterations of the
molecular players involved in the restriction point are crucial for cancer initiation,
as it allows cancer cells to proliferate independently of mitogenic or growth factor
stimuli.
Alterations of the pRb-E2F Pathway in Lung Cancer
Genetic alterations of the G1 to S phase transition have been reported to
play a key role in the pathogenesis and progression of both NSCLC and SCLC via
very different mechanisms (11). In SCLC, pRb is inactivated in more than 90% of
cases as a result of point mutations and abnormal mRNA expression (17).
Conversely, the majority of NSCLC cases exhibit abnormalities in the upstream
regulators of pRb, such as overexpression of Cyclin D1 or deletion of the p16INK4A
gene, which results in increased cyclin-CDK activity and pRb constitutive
inactivation through hyperphosphorylation (18,19). p16INK4A loss and Cyclin D1
overexpression are always inversely correlated with RB1 loss, suggesting they
exert their activities via pRb during lung transformation. Additionally, RB1 is
mutated in 15-30% of NSCLC cases, which correlates to poorer overall survival for
these patients.
Given the prevalence of aberrations in cell cycle control in lung tumors,
modulation of the cell cycle machinery has become an important therapeutic
strategy for the treatment of lung cancer. As discussed above, CDKs are often
dysregulated and overactive in lung cancer, resulting in uncontrolled cell cycle
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progression, in part through inactivating pRb. As such, selective inhibition of CDKs
has the potential to inhibit tumor cell proliferation by inducing cell cycle arrest (11).
Over the past three decades, extensive research has been done to develop small
molecule inhibitors of CDKs. First generation pan-CDK inhibitors evaluated in
clinical trials showed partial responses in NSCLC patients when combined with
standard cytotoxic agents; however, their toxicity and low activity excluded them
from being FDA approved (20). Further investigation has shifted from the use of
general pan-CDK inhibitors to the development of compounds that target specific
CDKs. Among these inhibitors, palbociclib (PD-0332991), a potent small-molecule
CDK4/6 inhibitor has been FDA-approved for the treatment of women with breast
cancer (21), and has shown efficacy in preclinical studies of NSCLC (22-26).
Canonical & Noncanonical Functions of the Retinoblastoma Protein
The RB1 gene product was initially discovered in retinoblastomas and is the
first reported tumor suppressor protein (27). In addition to retinoblastoma, genetic
alterations of RB1 have been found in osteosarcomas, renal cell carcinomas, as
well as adenocarcinomas of the breast, prostate, cervix, and lung (SCLC) (27).
Even in cancers without mutations or deletion of RB1 itself, disruption of other
nodes of the pRb-E2F pathways are observed, suggesting loss of pRb function is
a hallmark of human cancer (28). Following its discovery, extensive
characterization has been done on pRb’s role in cell cycle progression. In addition
to its interaction with the E2F family of transcription factors, pRb has been found
to associate with over 100 proteins, including a variety of transcription factors and
chromatin-associated proteins (29). Additionally, pRb forms regulatory complexes
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that can either repress or activate transcription (30-32). Due to its broad range of
binding partners, the direct targets of pRb activity are diverse and regulate other
processes such as differentiation, angiogenesis, genome stability, and apoptosis
(Figure 2) (33). Beyond cell cycle, other dysregulated cellular activities contribute
to malignant immortalization and transformation of normal lung tissue. Most of
these are intimately connected, such as cell cycle control and metabolic regulation.
Nutrient metabolism provides the required intermediates that allow cell cycle
progression, so accordingly alterations in metabolic pathways are observed in the
vast majority of human cancers.
Cancer Metabolism
Metabolism describes the complex, integrated network of chemical
reactions in which macromolecules are broken down or synthesized. These
processes are classified into two branches: catabolic pathways that produce
energy (namely adenosine triphosphate, ATP) and anabolic pathways that
synthesize molecules and require energy expenditure. This metabolic network is
tightly regulated in response to external stimuli through subsequent signaling
pathways and both positive and negative allosteric control of rate-limiting enzymes.
This allows for the rapid response to ever-changing cellular demands that vary
based on cell type, microenvironment, and proliferative state (34). Cancer cells
reprogram metabolic pathways in order to fulfill the biosynthetic requirements
associated with increased proliferation. Specifically, tumor cells alter their
metabolic activity to support either anabolic growth during nutrient-rich conditions
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Figure 2. Summary of the noncanonical functions of Rb. Rb regulates several
cellular processes relevant to cancer via interaction with numerous binding
partners and transcription factors (33). Reprinted with permission from [Springer
Nature] : [Nature] [NATURE REVIEWS CANCER] (Cellular mechanisms of
tumour suppression by the retinoblastoma gene), (Deborah L. Burkhart and Julien
Sage), [ãMACMILLIAN PUBLISHERS LIMITED] (2008).
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or catabolism to maintain survival during nutrient deprivation (35). The
dependencies on specific metabolic substrates exhibited by tumor cells are driven
by specific oncogenes and tumor suppressor genes that promote or inhibit
tumorigenesis, respectively. This reprogramming ability of tumor cells is
recognized as one of the hallmarks of cancer by Drs. Hanahan and Weinberg and
is now a field of extensive research (36). The major metabolic pathways that differ
between cancer cells and non-transformed cells are described below.
Glucose Metabolism and the Warburg Effect
To fulfill the biosynthetic demands of rapid proliferation, tumor cells must
increase the import of nutrients from their environment. Increased glucose uptake
is a distinguishing feature of tumor cells and is observed in most human cancers
(34,37). This difference is widely exploited diagnostically in Positron Emission
Tomography (PET) imaging where patients are administered radiolabeled analogs
of glucose such as
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F-fluorodeoxyglucose to visualize tumors (37). Under

physiologic oxygen concentrations, normal cells catabolize glucose to pyruvate,
the end product of glycolysis, followed by its conversion to acetyl-CoA to fuel the
tricarboxylic acid cycle (TCA cycle). The TCA cycle generates reduced
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide
(FADH2) cofactors, which serve as a source of electrons for mitochondrial
respiration and ATP (adenosine triphosphate) production. This process generates
up to 36 ATP per molecule of oxidized glucose. In contrast, cancer cells, even in
the presence of oxygen, preferentially use glycolysis to generate a larger fraction
of cellular ATP, a much less efficient form of energy production that yields only 2
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ATP per molecule of glucose (35-43). This phenomenon was first described by Dr.
Otto Warburg and is referred to as “aerobic glycolysis” or the “Warburg effect”;
wherein cancer cells increase glycolytic flux and divert pyruvate from the TCA
cycle to generate lactate regardless of oxygen availability (44,45). This was
originally postulated to result from mitochondrial dysfunction in cancer cells that
necessitated the exclusive use of glycolysis for energy production. However,
recent studies have shown intact tumors enhance both glycolysis and oxidative
phosphorylation simultaneously to meet both the anabolic and bioenergetic
demands of proliferation (35,46).
To compensate for the lower energy yield, cancer cells increase both the
rate of glucose uptake and glycolysis by increasing expression of glucose
transporters and glycolytic enzymes (37,47). Additionally, increased glycolytic flux
in cancer cells generates intermediates that are required to supply subsidiary
anabolic pathways with the necessary substrates to support cell growth and
proliferation (Figure 3). Both glucose-6-phosphate and fructose-6-phosphate
serve as substrates for the pentose phosphate pathway (PPP), which generates
the ribose moiety for nucleotide synthesis. Likewise, 3-phosphoglycerate
participates in one-carbon metabolism, where it is converted to formate, an
additional substrate for nucleotide synthesis. Glyceraldehyde-3-phosphate can be
converted to glycerol-3-phosphate, the carbon backbone required to synthesize
several types of lipids. Further, when glucose is catabolized by the TCA cycle, it
provides the necessary intermediates for nonessential amino acid production.
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Figure 3. Anabolic pathways support cancer cell growth. Increased glycolytic
flux in cancer cells generates intermediates that serve as substrates for anabolic
pathways such as nucleotide biosynthesis, lipid synthesis, and one-carbon
metabolism to sustain cell growth. From [DeBerardinis, R. J., and Chandel, N. S.
(2016) Fundamentals of cancer metabolism. Sci Adv 2, e1600200]. Reprinted with
permission from AAAS.
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Lactate Metabolism
In normal cells, pyruvate is converted to acetyl-CoA to fuel the TCA cycle,
yet cancer cells have been found to preferentially generate lactate from pyruvate.
This is in part due to the upregulation of lactate dehydrogenase A (LDHA), which
catalyzes pyruvate to lactate. This reaction provides several selective advantages
to cancer cells (39,48). Converting pyruvate to lactate regenerates NAD+ to allow
for

continued

glycolytic

activity

through

glyceraldehyde-3-phosphate

dehydrogenase (GAPDH). Moreover, excretion of lactate into the tumor
microenvironment lowers extracellular pH and increases the activity of
metalloproteases, aiding in the degradation of the extracellular matrix and inducing
cancer

metastasis

(49,50).

Likewise,

extracellular

lactate

promotes

an

immunosuppressive tumor microenvironment (51-53).
Lactate is trafficked in and out of the cell by monocarboxylate transporters,
MCT1 (import) and MCT4 (export). While cancer cells upregulate MCT4 and
primarily export lactate (54), recent studies have reported circulating lactate can
be imported through MCT1 and utilized as a TCA cycle carbon source in both
mouse models of lung cancer as well as in NSCLC patients (37,55,56). The
symbiosis of excreting and oxidizing imported lactate is postulated to allow glucose
to supply other anabolic pathways for cell growth while sustaining the bioenergetic
demands of rapid proliferation (43,57).
Glutaminolysis
In addition to glycolysis, cancer cells rely heavily on glutaminolysis to meet
their bioenergetic needs for cellular growth and proliferation (37). Glutamine is the
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most abundant amino acid in the plasma and is consumed at significantly higher
rates in cancer cells compared to normal tissue (47,58). Glutamine plays several
key roles in cancer metabolism as a nitrogen donor for nucleotide and protein
synthesis, a carbon source for lipid biosynthesis and energy production, and as a
precursor for the production of glutathione (Figure 4) (58-60). Increased
expression and activity of glutamine metabolizing enzymes and transporters have
been reported in multiple cancers (42,61). Additionally, targeting glutamine
utilization via glutamine depletion or inhibition of glutaminolytic enzymes has
shown efficacy against glutamine-dependent cancer types in vitro and in vivo
(47,61).
Glutaminolysis is a series of biochemical reactions that initiates when
glutamine is transported into the cytoplasm and is further metabolized through
deamination reactions catalyzed by mitochondrial or cytosolic glutaminases to
generate glutamate. In the cytoplasm, glutamine is used as a nitrogen donor for
biosynthesis of purine and pyrimidine nucleotides, or as a carbon source through
the conversion of glutamate for the antioxidant glutathione and nonessential amino
acids (42). Many cancer cells require de novo lipid biosynthesis which diverts
citrate from the TCA cycle to supply a source of lipogenic acetyl-CoA. Diminished
availability of citrate to the TCA cycle as a consequence of the Warburg effect
results in the need for anaplerotic replenishment of the TCA cycle, which can be
provided by glutaminolysis (47). In the mitochondria, glutamate serves as a source
of carbon for the TCA cycle, through production of alpha-ketoglutarate by
glutamate dehydrogenase (GLUD1) or various transaminases, such as aspartate
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Figure 4. Major metabolic and biosynthetic fates of glutamine. Glutamine
plays several key roles in cancer metabolism as a nitrogen donor for nucleotide
synthesis, a carbon source for lipid biosynthesis and energy production, and as a
precursor for glutathione biosynthesis. Abbreviations: glutamine transporter
(SLC1A5),

glutaminase

(GLS/GLS2),

glutamate

dehydrogenase

(GLUD),

reductive carboxylation (RC). Reprinted with permission from [Springer Nature] :
[Nature] [NATURE REVIEWS CANCER] (From Krebs to clinic: glutamine
metabolism to cancer therapy), (Brain J. Altman, Zachary E. Stine, and Chi V.
Dang), [ãMACMILLIAN PUBLISHERS LIMITED] (2016).
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aminotransferase (AAT), alanine aminotransferase (ALT), or phosphoserine
aminotransferase (PSAT). Oxidative metabolism of glutamine through the TCA
cycle also produces NADH and FADH2 for mitochondrial OXPHOS (oxidative
phosphorylation) to generate ATP necessary to sustain cellular bioenergetics.
Additionally, glutaminolysis allows cancer cells to mitigate oxidative stress
associated with rapid cell proliferation. Glutamine carbons exiting the TCA cycle
as malate are converted to pyruvate by malic enzyme, a reaction which generates
reduced nicotinamide adenine dinucleotide phosphate (NADPH) (62). NADPH is
required for the generation of reduced glutathione, a reactive oxygen species
scavenger that protects against oxidative stress.
In addition to serving as a source of anaplerotic carbon for the TCA cycle,
glutamine can also contribute to the production of acetyl-CoA for lipogenesis via
reductive carboxylation. Acetyl-CoA production from glutamine occurs via two
distinct mechanisms. First, the addition of CO2 to glutamine-derived aketoglutarate via isocitrate dehydrogenase 1 (IDH1) produces citrate, which is
transported to the cytosol to generate lipogenic acetyl-CoA (63). Likewise,
glutamine-derived malate can be converted to pyruvate by malic enzyme, which
can be further metabolized to lipogenic acetyl-CoA via citrate (47). Primarily
observed under hypoxic conditions, reductive carboxylation of a-ketoglutarate
provides a source of acetyl-CoA for lipogenesis that is independent of glucose,
allowing cells to divert glucose carbons into other anabolic pathways for growth
(64).
Pentose Phosphate Pathway
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Pentose phosphate pathway (PPP) is one of the major metabolic pathways
that promotes tumor cell proliferation by generating the substrates necessary for
nucleic acid synthesis to support DNA replication and RNA production. DNA and
RNA are polymers composed of varying combinations of nucleotides, made up of
an organic base (pyrimidines including cytosine, thymine, and uracil, and purines
which include adenine and guanine), one or more phosphate groups, and a
pentose sugar (ribose for RNA or deoxyribose for DNA). The major functions of
the PPP are to generate ribose-5-phosphate, the pentose phosphate moiety for
nucleotides, and generate NADPH through activity of glucose-6-phosphate
dehydrogenase (G6PD) (37).
PPP is comprised of two branches. In the oxidative arm, the glycolytic
intermediate glucose-6-phosphate is irreversibly converted to ribulose-5phosphate, yielding two molecules of NADPH. The non-oxidative arm is a
reversible pathway comprised of carbon-exchanging reactions beginning with
ribulose-5-phosphate and producing a final product of the glycolytic intermediates
fructose-6-phosphate and glyceraldehyde-3-phosphate, which can participate in
downstream metabolic pathways. Additionally, the non-oxidative arm produces
ribose-5-phosphate (R5P) as an intermediate which is used in nucleotide
synthesis. The regulatory enzymes that control the PPP include G6PD (oxidative
branch) and transketolase (non-oxidative branch).
Rapidly proliferating cells have a high demand for nucleotides and other
substrates for biosynthesis, therefore by providing NADPH and R5P for nucleotide
synthesis, the PPP is essential for tumor cells to mitigate oxidative stress while
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sustaining their anabolic demands (65,66). In proliferating tumor cells, G6PD
activity increases (67), and several PPP enzymes are reported to be upregulated
in multiple cancer subtypes (68,69). Recent studies suggest that in addition to its
proliferative role, the PPP has an important role in other aspects of cancer such as
drug resistance, apoptosis, invasion, and metastasis (68), making the PPP a
potential metabolic target for anti-cancer therapies.
One-Carbon Metabolism
One-carbon (1C) metabolism supports multiple physiological processes
including the production of 1C units for nucleotide synthesis, methylation reactions,
and the generation of reduced cofactors for redox homeostasis (70). 1C units are
largely derived from serine and glycine, both non-essential amino acids which can
be obtained exogenously or synthesized from other carbon sources (71). Serine
can be synthesized de novo from glucose through a series of enzymatic reactions
which convert 3-phosphoglycerate into serine, and glycine can be produced from
serine or threonine. Upregulation of enzymes within serine synthesis as well as
“serine addiction” has been observed in several human cancers (72). These
substrates are utilized by two primary 1C metabolism pathways: the folate cycle
and the methionine cycle (70). The folate cycle produces 1C units for nucleotide
synthesis as well as NADPH for maintaining redox balance, and has been the
target of many anti-cancer therapies (70). Conversely, the methionine cycle
produces methyl groups for methylation reactions and epigenetic modifications.
Lipid Metabolism
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Lipids are a broad category of hydrophobic or amphipathic molecules.
These are comprised of triacylglycerides that primarily serve as energy storage,
and phosphoglycerides, sterols, and sphingolipids, which are the major structural
components of plasma membranes. The main constituents of triacylglycerides and
phosphoglycerides are fatty acids, which consist of long hydrocarbon chains with
a carboxy-terminal group. To sustain their high proliferative rate, tumor cells
increase de novo lipid biosynthesis to supply the building blocks for membrane
formation (73,74). Oncogenes specifically enhance lipogenesis through the
upregulation of lipogenic enzymes such as ATP citrate lyase (ACLY), fatty acid
synthase (FASN), and acetyl-CoA carboxylase (ACC), as well as by increasing the
production of substrates for fatty acid synthesis (75-77). While tumor metabolic
reprogramming involves an increase in lipogenesis, recent studies have
highlighted a role for fatty acid oxidation in tumorigenesis (78). Fatty acids are a
rich energy source as their degradation produces acetyl-CoA which can undergo
mitochondrial oxidation, yielding large amounts of ATP through the TCA cycle and
mitochondrial respiration (73,74).
As stated previously, metabolic reprogramming is a hallmark of cancer that
is characterized by upregulation of multiple pathways including glycolysis,
glutaminolysis, PPP, one-carbon metabolism, and lipid metabolism. These specific
pathways not only aid in meeting the energy demands of rapid proliferating tumor
cells but supply the substrates to sustain large-scale biosynthesis. Additionally, the
majority of key oncogenic or tumor suppressor pathways observed in human
cancers contribute to the metabolic adaptations of tumor cells, which confer a
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selective advantage. Elucidating the unique metabolic phenotype of cancer cells
and the genetic drivers thereof allows for identification of new targets for the
potential development of novel therapies to improve patient outcome.
Metabolic Functions of pRb
Advances in our understanding of pRb function have highlighted roles that
extend beyond the cell cycle. Specifically, recent studies demonstrate a direct role
for pRb in controlling cellular metabolism in both normal and transformed cells.
The results of these studies are discussed below.
Glucose Metabolism
The earliest studies to highlight a role for pRb in controlling glucose
metabolism reported elevated expression and activity of hexokinase II (HK2), a
rate limiting enzyme in glycolysis, in retinoblastomas compared to normal retina
(79). Activation of pRb has also been shown to increase expression of several
glycolytic genes in oncogene-induced senescent cells, promoting both glycolysis
and OXPHOS (80). Notably, both glycolysis and OXPHOS were abolished upon
knockdown of RB1, highlighting a direct role for pRb in glycolytic activation. In
addition, genetic deletion of RB1 in retinal pigment epithelial cells decreases
glucose oxidation (81).
Several studies using transgenic mouse models to modulate pRb/E2F
pathway activity in vivo have demonstrated a role for pRb/E2F proteins in
regulating glucose tolerance. Deletion of E2F1 in adipocytes results in resistance
to diet-induced obesity (82), while loss of Rb1 in the hypothalamus leads to
glucose intolerance and obesity (83). Additionally, glucose uptake has been shown
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to promote pRb phosphorylation, thus increasing E2F activity in non-transformed
tissues (84,85). Conversely, glucose deprivation promotes the accumulation of
hypophosphorylated pRb in cultured mesangial cells (84). These data suggest that
pRb itself can be regulated in part by changes in glucose levels.
Nucleotide Synthesis
Among the first direct E2F-regulated targets to be described included genes
involved in nucleotide synthesis, such as dihydrofolate reductase (DHFR),
thymidylate synthase (TS), ribonucleotide reductase (RNR), and thymidine kinase
(TK1) (86,87). In the absence of pRb, the transcription of each of these genes
increases suggesting regulation by an pRb/E2F complex (88). Additionally, E2Fregulation of these targets is conserved during evolution, highlighting the
significance of this pathway in regulating nucleotide synthesis (89-91). Several
studies have shown a potential link between pRb-mediated control of nucleotide
synthesis and cell cycle regulation. Expression of a constitutively active pRb
protein results in both an increase in G1 cell population and a concomitant
decrease in dNTP pools (88). Likewise, pRb, but not p107 or p130, was found to
repress expression of RNR and DHFR in cells that had undergone oncogeneinduced senescence (92). Notably, knockdown of RB1 in these cells rescued the
changes in gene expression and allowed the cells to reenter the cell cycle.
Lipogenesis
Targets of the pRb/E2F pathway are often regulated by additional DNAbinding proteins which modulate their gene expression. One study identified a
genetic interaction between pRb and the sterol regulatory element-binding protein
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(SREBP) transcription factors (93). SREBPs are master regulators of lipogenic and
steroidogenic genes (94), thus demonstrating a new role for pRb in regulating lipid
metabolism. pRb was reported to target many of the genes encoding enzymes
within fatty acid and cholesterol biosynthesis (93). Moreover, the authors noted
these genes possess either E2F-consensus sequences, sterol regulatory
elements (SREs), or both. Lipidomic profiling coupled with transcriptomic analysis
of mouse embryonic fibroblasts (MEFs) revealed loss of Rb1 induces significant
alterations in their lipid composition and increases tumorigenic potential (95).
The TCA Cycle and Oxidative Metabolism
The pRb/E2F complex directly regulates mitochondrial activity by
suppressing the expression of enzymes that regulate mitochondrial pyruvate
oxidation (96,97). Specifically, pyruvate dehydrogenase kinase (PDK4) is a direct
target of pRb/E2F, and when activated, inhibits pyruvate dehydrogenase (PDH)
activity, resulting in decreased glucose oxidation within the TCA cycle. Contrary to
these findings, acute deletion of Rb1 in mice has been reported to increase
mitochondrial pyruvate oxidation from glucose in both the lung and colon (81).
Additionally, RB1 deficiency in triple negative breast cancers increases both
OXPHOS and mitochondrial protein translation (98).
In addition to glucose, cancer cells oxidize glutamine-derived carbon to fuel
the TCA cycle (58,59,99). Increased glutaminolysis and glutathione production has
been observed in pRb-deficient mammalian cells and Drosophila (91,100).
Specifically, loss of Rb1 increases expression of the glutamine transporter ASCT2
and the activity of glutaminase in MEFs (100). Notably, glutamine withdrawal

21

significantly increased ROS in these cells, suggesting pRb-deficient cells may be
susceptible to oxidative stress upon glutaminase inhibition.
While the mechanism by which pRb mediates metabolic changes has not
been fully elucidated, several studies has reported that E2F and pRb proteins bind
directly to promoters of genes that regulate metabolic flux (101). Moreover, pRb
can also exert its metabolic function through directly decreasing expression of
oncogenic signaling pathways that converge on metabolism, such as Ras or c-Myc
(86). An important gap in the evidence for a model by which pRb directly regulates
metabolism is that the majority of these studies were performed in non-transformed
cells or tissues. To date, there is no published study that directly assesses the
metabolic phenotype resulting from pRb dysfunction in lung cancer; particularly in
vivo. Based on the growing body of evidence that pRb plays a role in regulating
the metabolic state of the cell (86,87,95,102), we hypothesize that pRb modulates
metabolism in lung cancer through control of specific genes within pathways that
support cancer growth. This hypothesis will be examined by the following aims:
•

Specific Aim 1: Define the metabolic changes resulting from pRb
activation in NSCLC in vitro. This aim will be evaluated in A549 lung
adenocarcinoma cells and will implement several in vitro metabolic assays.
pRb activation will be achieved pharmacologically using an FDA-approved
CDK4/6 inhibitor.

•

Specific Aims 2 and 3: Characterize the changes in glucose utilization
(Aim 2) and metabolism of other TCA nutrient substrates (Aim 3)
resulting from Rb1 deletion in mouse lung tumors in vivo. These aims

22

will be evaluated using a combination of steady-state and stable-isotope
labeled metabolomics to assess global changes in either glucose,
glutamine, or lactate metabolism resulting from Rb1 loss in Kras-driven lung
tumors in vivo.
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CHAPTER 2: PALBOCICLIB TREATMENT ALTERS NUCLEOTIDE
BIOSYNTHESIS AND GLUTAMINE DEPENDENCY IN A549 CELLS
Introduction
Lung cancer is among the most frequently diagnosed cancers and is the
leading cause of cancer-related death worldwide, with an estimated 1.6 million
deaths each year (1-3). Of its subtypes, non-small cell lung cancer (NSCLC)
accounts for 85% of all lung cancer diagnoses (2). One of the hallmark events in
NSCLC pathogenesis is deregulation of the cell cycle (18,103). Transition from G1
to S phase during cell cycle progression is tightly regulated by phosphorylation of
the retinoblastoma protein tumor suppressor (pRb) by the CDK4/6-Cyclin D
complex. Activity of the CDK4/6-Cyclin D complex is strongly inhibited by p16
which induces cell cycle arrest. In the majority of NSCLC cases, p16 is mutated,
deleted, or epigenetically silenced, resulting in constitutive phosphorylation of pRb
and uncontrolled cell cycle progression (18,103). Pharmacologically, CDK4/6
inhibition phenocopies p16 activity (104,105).
Highly selective and potent small-molecule CDK4/6 inhibitors have shown
anti-tumor activity both in vitro and in vivo (104,105). Among these inhibitors,
palbociclib (PD-0332991) has been FDA-approved for the treatment of women with
breast cancer (21). Recently, palbociclib has shown efficacy either alone or as
combination therapy in preclinical studies of NSCLC (22-26). Mechanistically, the
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functional consequences of CDK4/6 inhibition apart from cell cycle arrest in
NSCLC are largely unknown; yet metabolic reprogramming in response to
palbociclib has revealed unique targetable vulnerabilities in several cancers
including pancreatic, colorectal, and leukemia (106-108). As such, we aimed to
characterize the metabolic phenotype induced by palbociclib in NSCLC.
Herein, we report that palbociclib treatment decreases nucleotide
biosynthesis and increases glutaminolysis without altering glycolysis in A549 lung
adenocarcinoma cells. Specifically, palbociclib-induced glutamine dependency
sensitizes A549 cells to glutaminase inhibition. Together, these data expand our
knowledge of understanding of the metabolic consequences of CDK4/6 inhibition
in NSCLC.
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Materials and Methods
Cell culture
The A549 lung adenocarcinoma cells were obtained from ATCC and
cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Hyclone)
and 50µg/ml gentamicin sulfate (Gibco). Cells were maintained at 5% CO2 at 37°C.
Palbociclib (PD-0332991) and CB-839 were purchased from Selleck Chemicals.
Cell transfections
Using Lipofectamine RNAiMAX reagent (Invitrogen), A549 cells were
transiently transfected with control siRNA (Silencer Select Negative Control #2,
Cat. No. 4390826, Ambion) or siRNA targeted to RB1 (Silencer Select s523, Cat.
No. 4390824, Ambion) for 24 hours prior to palbociclib treatment.
Cell proliferation and viability
A549 cells were seeded at 120,000 in 6-well plates (Corning), followed by
transfection and treatment with 1µM palbociclib or vehicle control. For glutaminase
inhibition studies, cells were seeded at 25,000 in 24-well plates (Corning), followed
by 25nM CB-839 treatment. Forty-eight hours post-treatment, cell number was
determined by trypan blue exclusion and enumeration using a hemocytometer.
Glucose uptake
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to
performing the assay. Cells were then incubated in glucose-free DMEM for 30 min,
followed by incubation with 5 µL of 2-[14C]-deoxyglucose (0.25µCi/ml; Perkin Elmer)
and three subsequent washes with ice-cold glucose-free DMEM. Lysates were
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collected in 500 µL of 0.1% SDS and scintillation counts (counts/min) were
measured using 350 µL of cell lysate on a Tri-Carb 2910 liquid scintillation analyzer
(Perkin Elmer Life Sciences). Protein concentration was determined using the BCA
assay (Pierce) according to the manufacturer’s protocol. Counts were normalized to
µg of protein.
3

H2O-Glycolysis Assay
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were

transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to
performing the assay. All cells were then incubated with 500 µL of complete medium
containing 2 µL of 1µCi of 5-[3H]-glucose for 60 min. Medium was then collected and
centrifuged for 5 min at 8,000 rpm to pellet cell debris. To isolate 3H2O generated
via enolase activity from the 5-[3H]-glucose added to the medium, 150 µL of
radiolabeled medium was added to open microcentrifuge tubes that were placed in
airtight scintillation vials containing 1 mL of H2O. Vials were parafilm sealed, and
3

H2O from the medium was allowed to equilibrate with the H2O in the scintillation

vials for 48 hours at 37°C. 3H2O that has diffused into the H2O was measured on a
Tri-Carb 2910 liquid scintillation analyzer (Perkin Elmer Life Sciences). Protein
concentration was determined using the BCA assay (Pierce) according to the
manufacturer’s protocol. Counts were normalized to µg of protein.
Mito stress test
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to
performing the assay. OCR measurements were conducted using a Seahorse
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XFe96 analyzer according to manufacturer’s protocol. One day prior to preforming
the assay, cells were reseeded at 35,000 in XFe96 cell culture plates and incubated
in 5% CO2 at 37°C. One hour prior to analysis, growth medium was replaced with
assay medium (DMEM minus phenol red and sodium bicarbonate that is
supplemented with 1mM pyruvate, 2mM L-glutamine, and 10mM glucose, pH 7.4)
and incubated in a non-CO2 incubator. During assay, 1µM oligomycin (Sigma), 2µM
FCCP (Sigma), and 1µM rotenone/antimycin A (Sigma) were sequentially injected
into each well in accordance with standard protocols. Absolute rates (pmoles/min)
were normalized to µg of protein.
Mito fuel flexibility assay
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to
performing the assay. OCR measurements were conducted using a Seahorse
XFe96 analyzer according to manufacturer’s protocol. One day prior to preforming
the assay, cells were reseeded at 35,000 in XFe96 cell culture plates and incubated
5% CO2 at 37°C. One hour prior to analysis, growth medium was replaced with
assay medium (DMEM minus phenol red and sodium bicarbonate that is
supplemented with 1mM pyruvate, 2mM L-glutamine, and 10mM glucose, pH 7.4)
and incubated in a non-CO2 incubator. Capacity and dependency for fatty acid,
glutamine, and glucose oxidation were determined through injections of the following
inhibitors in accordance with standard protocols: 4µM etomoxir (inhibits long chain
fatty acid oxidation), 3µM BPTES (inhibits glutamine oxidation), and 2µM UK5099
(inhibits glucose oxidation). The percent capacity for each fuel source was
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determined by dividing the OCR following inhibiting the two other pathways by the
OCR observed when all pathways are inhibited. The percent dependency for each
fuel source was determined by dividing the OCR observed when that specific
pathway is inhibited by the OCR observed when all pathways are inhibited. Absolute
rates (pmoles/min) were normalized to µg of protein.
Glycolysis stress test
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to
performing the assay. ECAR measurements were conducted using a Seahorse
XFe96 analyzer according to manufacturer’s protocol. One day prior to preforming
the assay, cells were reseeded at 35,000 in XFe96 cell culture plates and incubated
5% CO2 at 37°C. One hour prior to analysis, growth medium was replaced with
assay medium (DMEM minus phenol red and sodium bicarbonate that is
supplemented with 2mM L-glutamine, pH 7.4) and incubated in a non-CO2
incubator. During assay, 10mM glucose (Sigma), 1µM oligomycin (Sigma), and
50mM 2-deoxyglucose (Sigma)

were sequentially injected into each well in

accordance with standard protocols. Absolute rates (mpH/min) were normalized to
µg of protein.
Glucose 6-phosphate dehydrogenase activity assay
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to
performing the assay. The activity of G6PD from cell lysates was measured following
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the manufacturer’s protocol using the Glucose-6-Phosphate Dehydrogenase
Activity Assay Kit (Sigma, Cat. No. MAK015-1KT) and normalized to µg of protein.
[U-13C]-glucose tracer studies
Cells were seeded at 1 x 106 cells in 10cm dishes (Corning) and treated
with palbociclib or vehicle control for 48 hours. Cells were then labeled for six hours
with DMEM supplemented with 1g/L [U-13C]-glucose and 10% dialyzed fetal bovine
serum (Gibco). Cells were washed three times in ice-cold 1x PBS and quenched
with acetonitrile. Metabolites were extracted in acetonitrile:water:chloroform
(2ml:1mL:740µL). Samples were centrifuged at 3,000xg for 20 minutes at 4oC to
separate the polar, lipid, and cell debris layers. The remaining cell debris was reextracted with 500µL chloroform:methanol:butylated hydroxytoluene (2:1:1 mM)
and centrifuged at 22,000xg for 20 minutes at 4oC. The residual polar and lipid
fractions were combined with their respective fractions from the first extraction.
The polar fraction was vacuum-dried by lyophilization. The dried sample was
dissolved in 100 µL 50% acetonitrile and vigorously vortex-mixed for 3 minutes.
After centrifugation at 14,000rpm and 4oC for 20 min, 80µL of supernatant was
collected for 2DLC-MS/MS analysis.
2DLC-MS/MS analysis and data processing
All samples were randomly analyzed on a Thermo Q Exactive HF Hybrid
Quadrupole-Orbitrap Mass Spectrometer coupled with a Thermo DIONEX
UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham, MA, USA). The
UltiMate 3000 HPLC system was equipped with a reverse phase chromatography
(RPC) column and a hydrophilic interaction chromatography (HILIC) column that
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wwas configured in parallel to form a parallel 2DLC-MS system (109). To obtain
full MS data, every sample was analyzed by the parallel 2DLC-MS in positive mode
(+) and negative mode (-), respectively. For metabolite identification, one
unlabeled sample in each sample group was analyzed by 2DLC-MS/MS in positive
mode (+) and negative mode (-) to acquire MS/MS spectra at three collision
energies (20, 40 and 60 eV).
Data analysis for 2DLC-MS/MS
Full MS .raw files were first converted to .mzML format with msConvert tool,
a part of an open-source ProteoWizard suite, described in detail by Adusumilli and
Mallick (110). Isotopologue peak deconvolution and assignments were performed
using El-MAVEN (111). Peaks were assigned using a metabolite list generated
and verified using full scan MS and MS/MS spectra of unlabeled samples, as
described previously (112-114). The metabolite list contained metabolite names
and corresponding molecular formulae used to generate theoretical m/z values for
all possible isotopologues, and retention times for each metabolite. El-MAVEN
parameters for compound library matching were as follows: EIC Extraction Window
±7 ppm; Match Retention Time ± 0.60 min. For

13

C isotopologue peak detection,

the software criteria were set as follows: Minimum Isotope-parent correlation 0.20;
Isotope is within 5 scans of parent; Abundance threshold 1.0; Maximum Error To
Natural Abundance 100%. All assignments were visually inspected and compared
to unlabeled samples for reference. The peak list with corresponding abundances
was exported to a comma-separated (CSV) file and uploaded to the Polly workflow
for natural abundance correction and calculation of total pool size for each
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metabolite (by summing peak areas of each detected isotopologue) using Polly
Isocorrect module. Finally, the data were downloaded and plotted using Microsoft
Excel and GraphPad Prism software.
Real time-PCR
Total RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s protocol. The resulting total RNA (1µg) was
converted to cDNA using the High-Capacity RNA-to cDNA kit (applied biosystems).
Gene expression was determined by qPCR using the following Taqman Gene
Expression Assays: RB1 (Hs01078066_m1), RRM1 (Hs01040698_m1), RRM2
(Hs00357247_g1), PRPS2 (Hs00267624_m1), G6PD (Hs0166169_m1), ASCT2
(Hs01056542_m1), GLS (Hs01014020_m1), and GLUD1 (Hs01632647_g1). bactin (Hs01060665_g1) was used as an internal control. Data are reported as the
log (base 2) of the fold change with respect to siNeg treated with vehicle control.
Immunoblotting
Whole-cell lysates were prepared in RIPA lysis buffer (Pierce) containing
protease and phosphatase inhibitors. 20 µg of protein was separated on 10% Bolt
Bis-Tris gels (Invitrogen) and transferred to PVDF membrane. Membranes were
blocked with 5% BSA in TBS-T and probed with 1:1000 dilution of anti-phospho-Rb
(Cell Signaling, #3590S) overnight at 4oC. Membranes were washed and incubated
with HRP-conjugated anti-rabbit (1:5,000) secondary antibodies for one hour.
Protein detection was performed by ECL chemiluminescent reagent (Amersham)
exposure. 1:20,000 dilution of anti-b-actin antibody (Sigma, A2228) was used to
assess protein loading.
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Statistical analysis
Statistical analyses were carried out using GraphPad Prism. All numerical
data are reported as mean ± SEM. For each experiment, statistical analysis,
replicates, and p values are described in their respective figure legends.
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Results
Palbociclib treatment does not alter glycolysis in A549 cells
To assess the role of CDK4/6 inhibition on metabolism in NSCLC, we
utilized A549 lung adenocarcinoma cells. While these cells express wild-type pRb,
they

harbor

a

p16INK4A

deletion

that

results

in

constitutive

pRb

hyperphosphorylation and inactivation. Our prior studies have demonstrated
treatment with palbociclib inhibits the phosphorylation of pRb and results in
decreased cell proliferation (Figure 5A,B) (115). Recent studies have
demonstrated palbociclib alters glucose metabolism in multiple cancer subtypes
(116-118). To monitor the effect of palbociclib on glucose uptake, we performed
radiolabeled glucose uptake assay using 2-[14C]-deoxyglucose in A549 cells. As
CDK4/6 inhibition can have metabolic effects independent of pRb, these studies
were performed following palbociclib treatment with simultaneous knockdown of
RB1 (Figure 5C). We observed no significant change in glucose uptake upon
palbociclib treatment in A549 cells (Figure 6A). We next examined, as a
measurement of glycolytic activity, the release of 3H2O from 5-[3H]-glucose via
enolase activity. We found that palbociclib decreases 3H2O production in an pRbdependent manner (Figure 6B). However, it has been reported that the use of 5[3H]-glucose to measure glycolysis can overestimate glycolytic rate, as both the
pentose phosphate pathway (PPP) and glycolysis generate the substrate for
enolase (119). To better assess glycolytic function in response to palbociclib
treatment, we performed a glycolysis stress test using a Seahorse XFe96 analyzer.
Interestingly, we observed no difference in the extracellular acidification rate (ECAR)
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Figure 5. Palbociclib decreases pRb phosphorylation and proliferation of
A549 lung cancer cells. (A) Western blot analysis phosho-pRb (p-pRb) levels and
(B) cell proliferation A549 cells following 48-hour 1µM palbociclib treatment. (C)
Confirmation of pRb knockdown by siRNA by qPCR. For (A,C) b-actin was used
as a loading and internal control, respectively. For (B,C) values represent mean ±
SEM, analyzed by unpaired t-test (n=5, independent experiments) (B) and twoway ANOVA with Sidak’s post-hoc multiple comparisons (n=3, independent
experiments) (C). Statistical significances between each group are as follows:
***p<0.001.
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Figure 6. Palbociclib has no effect on glucose uptake but decreases 3H2O
production in an pRb-dependent manner. (A) Glucose uptake assessed by
intracellular 2-[14C]-deoxyglucose, and (B) Enolase activity measured by 3H2O
production in A549 cells following knockdown of pRb and 48-hour treatment with
1µM palbociclib. Values represent mean ± SEM, analyzed by two-way ANOVA
with Sidak’s post-hoc multiple comparisons (n=3, independent experiments).
Statistical significances between each group are as follows: ***p<0.001.
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upon palbociclib treatment (Figure 7), suggesting palbociclib does not alter
glycolysis in A549 cells.
To define global changes in glucose utilization resulting from palbociclib
treatment, we performed [U-13C]-glucose tracer studies. Utilization of ubiquitously
labeled glucose results in the intracellular generation of 13C labeling of the hexose
and triose sugar intermediates within the glycolytic pathway; leading to fully labeled
pyruvate (m+3) and lactate (m+3) (Figure 8). Palbociclib has been shown to
increase glycolytic flux in both breast and pancreatic cancers (106,117,118);
however, consistent with our glycolysis stress test findings, palbociclib does not
alter glucose carbon incorporation into glycolytic intermediates in A549 cells
(Figure 9). Our data suggest that the palbociclib-mediated effects on glycolysis
may be tissue-specific.
CDK4/6 inhibition decreases glucose flux through the PPP
Given we observed a decrease in 3H2O production as measured from
radiolabeled 5-[3H]-glucose, but did not observe a corresponding decrease in ECAR
or glucose carbon incorporation into glycolytic intermediates from our [U-13C]glucose tracer studies, we hypothesized palbociclib may alter PPP activity. We
observed decreased glucose carbon incorporation into sedoheptulose 7phosphate, an intermediate in the PPP. Treatment also decreased m+5 labeling of
several nucleotides, which is indicative of a fully labeled ribose moiety derived from
PPP activity (Figure 10,11). Together, these data suggest palbociclib decreases
glucose metabolism through the PPP. Consistent with our labeling data, palbociclib

37

Glycolytic Function

A
ECAR (mpH/min/µg protein)

20

Glucose Oligomycin 2-DG

siNeg Vehicle
siNeg Palbociclib

15

siRB1 Vehicle
siRB1 Palbociclib

10
5
0
1

8 14 21 27 34 40 47 53 60 66 73

Time (minutes)

6

Glycolysis

4

2

0
siNeg

3

Non-Glycolytic
Acidification

2

1

0
siNeg

siRB1

siRB1

E
15

Glycolytic Capacity

10

5

0
siNeg

ECAR (mpH/min/µg protein)

D
ECAR (mpH/min/µg protein)

C
ECAR (mpH/min/µg protein)

ECAR (mpH/min/µg protein)

B

siRB1

8

Glycolytic Reserve

6
4
2
0
siNeg

Vehicle

siRB1

Palbociclib

Figure 7. Palbociclib does not alter glycolytic function in vitro. (A) Glycolysis
stress test measured in A549 cells following knockdown of pRb and 48-hour
treatment with 1µM palbociclib. (B-E) ECAR assessment of (B) glycolysis, (C) nonglycolytic acidification, (D) glycolytic capacity, and (E) glycolytic reserve. Values
represent mean ± SEM, analyzed by two-way ANOVA with Sidak’s post-hoc
multiple comparisons (n=3, independent experiments).
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Figure 8. Cartoon of [U-13C]-glucose fate mapping though glycolysis. Red
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Figure 9. Palbociclib does not alter glucose carbon incorporation into
glycolytic intermediates in A549 cells. (A-F) Fractional enrichment of m+6
labeled glucose 6-phosphate (A) and fructose 6-phosphate (B), and m+3 labeled
3-phosphoglycerate (C), phosphoenolpyruvate (D), pyruvate (E), and lactate (F)
following 48-hour treatment with 1µM palbociclib. Values represent mean ± SEM,
analyzed by unpaired student’s t-test (n=6, technical replicates).
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Figure 10. Cartoon of [U-13C]-glucose fate mapping though the pentose
phosphate pathway. Red circles indicate 13C.
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Figure 11. Palbociclib decreases glucose carbon incorporation into the PPP
in A549 cells. (A) Fractional enrichment of m+5 labeled nucleotides and
nucleosides, and (B) m+7 sedoheptulose 7-phosphate following 48-hour treatment
with 1µM palbociclib. Values represent mean ± SEM, analyzed by unpaired
student’s t-test (n=6, technical replicates). Statistical significances between each
group are as follows: **p<0.01 and ***p<0.001.
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decreased glucose 6-phosphate dehydrogenase (G6PD) activity in an pRbdependent manner (Figure 12A). Additionally, we measured expression of G6PD
and

other

genes

within

nucleotide

synthesis

including

phosphoribosyl

pyrophosphate synthetase 2 (PRPS2) and ribonucleotide reductase 1/2 (RRM1/2).
Palbociclib decreased expression of RRM2 in an pRb-dependent manner but does
not significantly alter expression of other genes within nucleotide synthesis (Figure
12B-E).
Palbociclib increases oxygen consumption in A549 cells
CDK4/6 inhibition has been reported to increase both mitochondrial mass
and oxygen consumption in pancreatic cancer (106). As such, we assessed
mitochondrial activity by measurement of the oxygen consumption rate (OCR) in
A549 cells following palbociclib treatment. Consistent with other cancer types
(106,107), we observed a significant increase in several parameters of
mitochondrial activity including basal (p = 0.0019) and non-mitochondrial
respiration (p = 0.0115) (Figure 13). While two-way ANOVA revealed no
interaction between palbociclib treatment and pRb status (p = 0.113), palbociclib
increased basal OCR 1.4-fold, which was reduced to 1.2-fold in the absence of
pRb.
To determine if the increase in basal oxygen consumption upon palbociclib
treatment is the result of increased glucose oxidation, we measured TCA cycle
metabolites following [U-13C]-glucose labeling in A549 cells. Pyruvate (m+3)
generated from glycolysis can be metabolized to lactate by lactate dehydrogenase
(LDH) or oxidized in the TCA cycle through pyruvate dehydrogenase (PDH) or
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Figure 12. Palbociclib decreases G6PD activity and RRM2 transcript levels
in A549 cells. (A) G6PD activity assessed in A549 cells following knockdown of
pRb and 48-hour treatment with 1µM palbociclib. (B-E) qPCR analysis of glucose
6-phosphate dehydrogenase (G6PD), phosphoribosyl pyrophosphate synthetase
2 (PRPS2), and ribonucleotide reductase 1/2 (RRM1/2) in A549 cells following
knockdown of pRb and 48-hour treatment with 1µM palbociclib. Values represent
mean ± SEM, analyzed by two-way ANOVA with Sidak’s post-hoc multiple
comparisons (n=3, independent experiments). Statistical significances between
each group are as follows: **p<0.001.
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Figure 13. Palbociclib increases mitochondrial respiration in A549 cells. (A)
Oxygen consumption rate (OCR) measured in A549 cells following knockdown of
pRb and 48-hour treatment with 1µM palbociclib. (B-G) OCR assessment of (B)
basal respiration, (C) non-mitochondrial respiration, (D) maximal respiration (E) ATP
production, (F) proton leak, and (G) spare capacity. Values represent mean ± SEM,
analyzed by two-way ANOVA (n=3, independent experiments).
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pyruvate carboxylase (PC). PDH entry of pyruvate carbon is indicated by m+2 (1st
turn)/m+4 (2nd turn) isotopologues, while PC activity is observed by m+3
isotopologue labeling of TCA intermediates. (Figure 14). While there was no
consistent effect on PDH-mediated pyruvate carbon entry (m+2/m+4), we found
that palbociclib increased m+3 labeling of several TCA metabolites, suggesting
palbociclib increases PC activity for anaplerosis in A549 cells (Figure 15).
Palbociclib sensitizes A549 cells to glutaminase inhibition in an pRbdependent manner
We next sought to determine whether palbociclib alters the capacity
to metabolize or the dependency on specific TCA fuels such as glucose, glutamine,
or fatty acids for mitochondrial function. We performed the Mito Fuel Flex assay
using a Seahorse XFe96 analyzer to assess the contributions of glucose,
glutamine, and fatty acids as fuel sources to maintain basal mitochondrial
respiration. Palbociclib had no effect on the overall capacity of A549 cells to utilize
glucose, but did decrease the cells’ dependency on glucose to maintain basal
respiration, indicating glucose is not the sole fuel source for the TCA cycle in
palbociclib treated cells (Figure 16A,D). While palbociclib increases the capacity
to oxidize fatty acids, it has no effect on the cells’ dependency for fatty acid
oxidation, suggesting that inhibition of fatty acid oxidation would have no effect on
the viability of palbociclib treated cells (Figure 16B,E). Notably, we observed an
increase in both glutamine capacity and dependency in A549 cells upon palbociclib
treatment (Figure 16C,F).
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Figure 15. Palbociclib increases PC-mediated anaplerosis in A549 cells. (AD) Fractional enrichment of the TCA metabolites (A) citrate, (B) fumarate, (C)
malate, and (D) aspartate in A549 cells following 48-hour treatment with 1µM
palbociclib. Values represent mean ± SEM, analyzed by unpaired student’s t-test
for each metabolite isotopologue (vehicle vs. palbociclib) (n=6, technical
replicates). Statistical significances between each group are as follows:
***p<0.001.
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Figure 16. Palbociclib increases glutamine dependency in A549 cells. (A)
glucose, (B) glutamine, and (C) fatty acid capacity, and (D) glucose, (E) glutamine,
and (F) fatty acid dependency measured by the Mito Fuel Flex assay in A549 cells
following 48-hour treatment with 1µM palbociclib. Values represent mean ± SEM,
analyzed by unpaired student’s t-test (n=3, independent experiments). Statistical
significances between each group are as follows: *p<0.05 and **p<0.01.
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The enzyme glutaminase converts glutamine to glutamate and is highly
expressed in cancer cells (58,59,62). CB-839 is a highly potent glutaminase
inhibitor that has shown anti-tumor activity in both in vitro and in vivo models of
lung cancer (120). We hypothesized that the observed increase in glutamine
dependency may sensitize palbociclib treated cells to glutaminase inhibition.
Although palbociclib does not significantly alter expression of genes within
glutamine utilization, including the glutamine transporter, ACTS2, glutaminase
(GLS), or glutamine dehydrogenase (GLUD1) (Figure 17), we observed a
significant decrease in proliferation in cells treated with CB-839 and palbociclib,
than with palbociclib or CB-839 alone (Figure 18). Additionally, statistical analysis
found a significant interaction between inhibitor sensitivity and pRb status (p <
0.0001), suggesting pRb expression is necessary for palbociclib to exert its effect
on glutamine dependency. Together, our data highlight that palbociclib-induced
metabolic adaptations have the potential to be therapeutically exploited.
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Figure 17. Palbociclib does not alter expression of genes within glutamine
utilization. qPCR analysis of the glutamine transporter ASCT2, glutaminase
(GLS), and glutamate dehydrogenase (GLUD1) in A549 cells following knockdown
of pRb and 48-hour treatment with 1µM palbociclib. Values represent mean ± SEM,
analyzed by two-way ANOVA (n=3, independent experiments).
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Figure 18. Palbociclib sensitizes A549 cells to glutaminase inhibition. Cell
proliferation following knockdown of pRb and 48-hour treatment with 1µM
palbociclib and/or 25nM CB-839. Values represent mean ± SEM, analyzed by twoway ANOVA with Sidak’s post-hoc multiple comparisons (n=3, independent
experiments). Statistical significances between each group are as follows:
***p<0.001.
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Discussion
While cancer metabolism as a target for therapeutic intervention has been
extensively studied (35,38,42,48,61), there is a growing appreciation for cell cycle
proteins

that

display

metabolic

regulatory

functions

(33,86,96,104,121).

Additionally, with the increase in utilization of CDK4/6 inhibitors in the clinic, there
is a need for better understanding of the metabolic consequences of CDK4/6
inhibition. In the current study, we report that activation of pRb via treatment with
the CDK4/6 inhibitor palbociclib in A549 lung adenocarcinoma cells results in a
metabolic shift wherein palbociclib alters glucose and glutamine utilization.
Specifically, palbociclib decreases glucose metabolism through the PPP via
inhibition of G6PD activity (Figure 12A), while increasing glutaminolysis to
maintain basal mitochondrial function (Figure 16B,E). Moreover, both changes
observed were rescued upon knockdown of pRb, suggesting the metabolic
consequences of CDK4/6 inhibition in A549 cells with respect to these metabolic
processes are pRb-dependent.
Recently, it has been demonstrated that CDKs can directly regulate
metabolism via phosphorylation of metabolic enzymes. Specifically, the cyclin
D3/CDK6 kinase complex can phosphorylate pyruvate kinase M2 and 6phosphofructokinase (108). The authors report that this results in shunting of
glycolytic intermediates into the PPP and the serine synthesis pathways.
Treatment with palbociclib reduces this flux, resulting in NADPH and glutathione
depletion and inducing apoptosis. Consistent with these findings, we observed a
decrease in glucose carbon incorporation into nucleotides (Figure 11A). This was
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in part due to decreased activity of the rate limiting enzyme in the PPP, G6PD
(Figure 12A). As A549 cells express both CDK4 and CDK6, it remains unclear
whether the observed decrease in G6PD activity is due the effects of the cyclin
D3/CDK6 kinase complex inhibition.
As previously described, palbociclib increases mitochondrial activity in vitro
(106,107). Specifically, CDK4/6 inhibition increases glutamine utilization and
sensitivity to glutaminase inhibition in breast and colorectal cancer cells (107). The
authors reported that the increase in glutaminolysis was a result of enhanced MYC
signaling in response to CDK4/6 inhibition. We did observe a modest increase in
basal oxygen consumption upon palbociclib treatment (Figure 13B), which is
driven, in part, by enhanced glutaminolysis (Figure 16B,E). We postulate that this,
in turn, sensitized A549 cells to treatment with CB-839 (Figure 18). MYC exerts
its effect on glutaminolysis specifically via upregulation of the glutamine transporter
ASCT2 and GLS (122,123). As we did not observe significant upregulation of these
genes (Figure 17), our data suggest the enhanced glutaminolysis in this context
may be independent of MYC signaling.
While other studies have reported enhanced glycolysis upon CDK4/6
inhibition or deletion, or direct activation of pRb itself (80,106,107), our [U-13C]glucose and ECAR studies revealed no significant changes in glycolytic function
upon palbociclib treatment (Figure 6,7,9). One possible explanation for this
discrepancy is the acute treatment duration for our studies (48 hours compared to
120 hours). Prolonged CDK4/6 inhibition (96 hours to two weeks) has been
reported to induce both senescence and autophagy in vitro (106,107,124,125).

54

Many of the reported metabolic consequences of palbociclib treatment are also
metabolic hallmarks of these cellular processes. Senescent cells exhibit elevated
glycolysis and mitochondrial metabolism, resulting in increased mitochondrial
mass and production of reactive oxygen species (ROS) (126,127). This triggers
autophagy and protein degradation to mitigate the cellular stress induced by
senescence (128). In addition to enhanced glycolysis, palbociclib treatment has
been reported to increase amino acid catabolism, mitochondrial abundance and
activity, and ROS production (106,107). Our studies are unique in that we have
identified potential senescence-independent metabolic consequences of CDK4/6
inhibition.
Given the recent use of palbociclib in clinical trials for NSCLC patients,
understanding the noncanonical functions CDK4/6 inhibition in cancer cell
metabolism are important for identifying potential combination therapies to improve
patient outcome. Our studies demonstrate that palbociclib treatment increases
glutamine dependency and sensitizes cells to the glutaminase inhibitor, CB-839.
While the precise mechanism by which palbociclib mediates increased
glutaminolysis remains unclear, pRb expression is required for palbociclib to exert
its function in this context. Together, our data highlight the metabolic changes upon
palbociclib treatment in A549 cells and may support the of targeting CDK4/6
inhibition in combination with glutaminase inhibitors in NSCLC patients with pRbproficient tumors.
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CHAPTER 3: LOSS OF RB1 ENHANCES GLYCOLYTIC METABOLISM IN
KRAS-DRIVEN LUNG TUMORS IN VIVO
Introduction
Lung cancer is the leading cause of cancer-related deaths for both men and
women worldwide, with the 5-year survival rate being less than 18% (1). Of its
subtypes, non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer
diagnoses (2). Deregulation of the cell cycle is a major driver of tumorigenesis, and
aberrant expression of cell cycle proteins in the retinoblastoma protein, E2F factor
(pRb-E2F) pathway have been found to play a key role in the pathogenesis of
NSCLC (18,103). pRb is a tumor suppressor that is reported to be dysfunctional in
the majority of human cancers. Canonically, pRb functions to regulate cell cycle
progression by repressing the transcriptional activity of the E2F family of
transcription factors, inhibiting S phase entry (129). In most NSCLC cases, pRb
inactivation occurs via hyperphosphorylation; however, in 15-30% of cases, Rb1,
the gene encoding pRb, is mutated, which correlates to poorer overall survival for
these patients (33,130).
Advances in our understanding of pRb function have highlighted additional
biochemical pathways under pRb regulation beyond cell cycle progression.
Emerging evidence supports a direct role for pRb in regulating metabolic pathways
such

as

glycolysis,

glutaminolysis,
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lipogenesis,

mitochondrial

oxidative

phosphorylation, and reactive oxygen species metabolism (86,87,95,102). pRb
can exert its metabolic function via interaction with the E2F family of transcription
factors and altering expression of metabolic enzymes and transporters (81,96,97).
Additionally, acute loss of Rb1 increases mitochondrial pyruvate oxidation in
normal lung tissue; however, the metabolic effects of pRb loss during lung cancer
development are largely unknown.
Herein, we report that loss of Rb1 in an in vivo mutant Kras-driven model of
lung cancer enhances glycolytic metabolism without altering mitochondrial
pyruvate oxidation. Moreover, loss of Rb1 has no significant effect on TCA
anaplerosis or utilization of alternative nutrient sources apart from glucose. These
data expand our knowledge of understanding of the metabolic phenotype resulting
from pRb dysfunction in a widely used model of lung cancer.
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Materials and Methods
Mouse model and adenoviral infection
All animal studies were approved by the University of Louisville’s
Institutional

Animal

Care

and

Use

Committee.

KrasLSL/G12D/Rb1+/+ and

KrasLSL/G12D/Rb1lox/lox mice were generated by breeding KrasLSL/G12D/Rb1+/lox mice
as described in (131). Lung tumors were induced in 8-week old KrasLSL/G12D/Rb1+/+
and KrasLSL/G12D/Rb1lox/lox mice by intratracheal instillation of 2.5x107 PFU of
adenovirus expressing Cre-recombinase (Vector Development Lab, Baylor
College

of

Medicine).

For

all

studies,

age-matched

non-instilled

KrasLSL/G12D/Rb1lox/lox mice were used as normal lung controls.
Kaplan-Meier analysis
Eight-weeks post-surgery, KrasLSL/G12D/Rb1+/+ and KrasLSL/G12D/Rb1-/- mice
were examined twice weekly. Mice were sacrificed upon visible signs of advanced
morbidity such as lethargy, weight loss (>15%), hunching, and distressed rapid
breathing. The logrank P value and hazard ratio (HR) was calculated using KaplanMeier survival analysis in GraphPad Prism software.
[U-13C]-glucose, [U-13C, 15N]-glutamine, and [U-13C]-lactate tracer studies
Upon tumor onset (KrasLSL/G12D/Rb1-/-: 10-16 weeks; KrasLSL/G12D/Rb1+/+:
15-20 weeks; determined by symptomatic observation of labored breathing) mice
were injected via the tail vein with either 80µL 25%w/v [U-13C]-glucose or 200µL
of 36.2 mg/ml [U-13C,

15

N]-glutamine, three times, 15 minutes apart as described

in (132,133). [U-13C]-lactate studies were performed following the same protocol
using 100µL of 300mM [U-13C]-lactate. At 15 minutes after the last injection, mice
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were sacrificed by cervical dislocation, blood collected, and lung tumors or normal
lung were excised and flash frozen in liquid nitrogen. Number of animals per group
+/+

-/-

(normal lung, Rb1 , and Rb1 lung tumors) for each labeled nutrient is depicted
within their respective figure legends.
Plasma [U-13C]-glucose, [U-13C, 15N]-glutamine, and [U-13C]-lactate analysis
Blood was collected from mice by cardiac puncture following euthanasia
and processed as described in (133). Up to 150µL of blood was collected in K2EDTA microtubes and incubated at room temperature for 5 minutes, then placed
on ice. Plasma was separated from blood cells by centrifugation at 3,500xg for 15
minutes at 4oC. For [U-13C]-glucose and [U-13C]-lactate studies, plasma was
deproteinized by trichloroacetic acid (TCA) extraction by adding 300µL of 1:10 TCA
dilution to 30µL plasma. Samples were centrifuged at 15,000rpm for 30 minutes at
4oC and the supernatant was vacuum dried by lyophilization. Samples were
redissolved in 650µL D2O and analyzed by 2D-NMR. For [U-13-C,

15

N]-glutamine

studies, metabolites were extracted from plasma by adding 130µL methanol:water
(80:20) to 10µL plasma. Samples were vortexed for 10 seconds, incubated for 10
minutes at 4oC, followed by centrifugation at 16,000xg for 10 minutes at 4oC. The
supernatant was vacuum dried by SpeedVac, followed by 2DLC-MS/MS analysis.
Metabolite tissue sample preparation for tracer studies
To extract metabolites from tissue samples, up to 20mg of pulverized frozen
tissue was extracted for polar and lipid metabolites as described in (132) with minor
modifications. In brief, metabolites were extracted in acetonitrile:water:chloroform
(1ml:750µL:500µL). Samples were centrifuged at 3,000xg for 20 minutes at 4oC to
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separate the polar, lipid, and tissue debris layers. The remaining tissue debris was
re-extracted with 500µL chloroform:methanol:butylated hydroxytoluene (2:1:1 mM)
and centrifuged at 22,000xg for 20 minutes at 4oC. The residual polar and lipid
fractions were combined with their respective fractions from the first extraction.
The polar fraction was vacuum-dried by lyophylization. The dried sample was
dissolved in 100 µL 50% acetonitrile and vigorously vortex-mixed for 3 minutes.
After centrifugation at 14,000rpm and 4oC for 20 min, 80µL of supernatant was
collected for 2DLC-MS/MS analysis.
Sample preparation and derivatization for steady-state metabolomics
Up to 20mg of pulverized frozen tissue was extracted in 1ml of 50%
methanol

and

separated

into

polar

(aqueous

layer),

and

protein/DNA/RNA/glycogen pellet. The polar fraction was dried at 10-3 mBar using
a SpeedVac (Thermo) followed by derivatization. The protein/DNA/RNA/glycogen
pellet was washed 4 times with 50% methanol and once with 100% methanol.
Samples were centrifuged at 15,000rpm for 10 minutes between washes.
Hydrolysis of the protein/DNA/RNA/glycogen pellet was performed by first
resuspending the dried pellet in diH2O followed by the addition of equal parts 2N
HCl. Samples were vortexed thoroughly and incubated at 95°C for 2 hours. The
reaction was quenched with 100% methanol with 40µM L-norvaline (as an internal
control). The sample was incubated on ice for 30 minutes and the supernatant was
collected by centrifugation at 15,000rpm at 4°C for 10 minutes. The collected
supernatant was subsequently dried by vacuum centrifuge at 10-3 mBar.
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Dried polar and hydrolyzed pellet samples were derivatized by the addition
of 50µl of 20mg/ml methoxyamine in pyridine to the dried sample in the 1.5ml
Eppendorf tube. Samples were incubated for 1 hour and 30 minutes at 30°C.
Tubes were then centrifuged at 15,000rpm for 10 minutes. Supernatant of each
tube was transferred to v-shaped amber glass chromatography vial. Lastly,
addition of 80ul N-methyl-trimethylsilyation (MSTFA) occurred with an incubation
period at 37oC for 30 minutes. Derivatized samples were then analyzed by GCMS.
GC-MS analysis and data processing
GC-MS protocols were similar to those described previously (134,135)
except a modified temperature gradient was used for GC: Initial temperature was
130°C, held for 4 minutes, rising at 6°C/minute to 243°C, rising at 60°C/minute to
280°C, held for 2 minutes. The electron ionization (EI) energy was set to 70 eV.
Scan (m/z:50-800) and full scan mode were used for metabolomics analysis. Mass
spectra were translated to relative metabolite abundance using the Automated
Mass Spectral Deconvolution and Identification System (AMDIS) software
matched to the FiehnLib metabolomics library (available through Agilent) for
retention time and fragmentation pattern matching with a confidence score of > 80
(136-138). Data was further analyzed using the Data Extraction for Stable Isotopelabelled Metabolites (DEXSI) software package (139). Relative abundance was
corrected for recovery using the L-norvaline and adjusted to protein input. Rapid
quantitation of derivatized protein/DNA/RNA/glycogen pellet is as described in
(140). Unsupervised hierarchical clustering analysis of steady-state metabolite
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levels was performed using the online Morpheus software tool from the Broad
Institute.
2DLC-MS/MS analysis and data processing
All samples were randomly analyzed on a Thermo Q Exactive HF Hybrid
Quadrupole-Orbitrap Mass Spectrometer coupled with a Thermo DIONEX
UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham, MA, USA). The
UltiMate 3000 HPLC system was equipped with a reverse phase chromatography
(RPC) column and a hydrophilic interaction chromatography (HILIC) column that
was configured in parallel to form a parallel 2DLC-MS system (109). To obtain full
MS data, every sample was analyzed by the parallel 2DLC-MS in positive mode
(+) and negative mode (-), respectively. For metabolite identification, one
unlabeled sample in each sample group was analyzed by 2DLC-MS/MS in positive
mode (+) and negative mode (-) to acquire MS/MS spectra at three collision
energies (20, 40 and 60 eV).
Data analysis for 2DLC-MS/MS
Full MS .raw files were first converted to .mzML format with msConvert tool,
a part of an open-source ProteoWizard suite, described in detail by Adusumilli and
Mallick (110). Isotopologue peak deconvolution and assignments were performed
using El-MAVEN (111). Peaks were assigned using a metabolite list generated
and verified using full scan MS and MS/MS spectra of unlabeled samples, as
described previously (112-114). The metabolite list contained metabolite names
and corresponding molecular formulae used to generate theoretical m/z values for
all possible isotopologues, and retention times for each metabolite. El-MAVEN
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parameters for compound library matching were as follows: EIC Extraction Window
±7 ppm; Match Retention Time ± 0.60 min. For

13

C isotopologue peak detection,

the software criteria were set as follows: Minimum Isotope-parent correlation 0.20;
Isotope is within 5 scans of parent; Abundance threshold 1.0; Maximum Error To
Natural Abundance 100%. All assignments were visually inspected and compared
to unlabeled samples for reference. The peak list with corresponding abundances
was exported to a comma-separated (CSV) file and uploaded to the Polly workflow
for natural abundance correction and calculation of total pool size for each
metabolite (by summing peak areas of each detected isotopologue) using Polly
Isocorrect module. Finally, the data were downloaded and plotted using Microsoft
Excel and GraphPad Prism software.
NMR analysis
NMR spectra were recorded at 293 K at 14.1T initially on a Varian Inova
NMR spectrometer with a 5 mm HCN cold probe and later on a Bruker Advance
Neo NMR spectrometer equipped with a 5 mm Prodigy probe. Typically, presaturation at very low power was employed in a pulse sequence during the recycle
delay (3 seconds) to saturate any residual water (HOD) in the samples before
acquiring for about 2 seconds. Generally, 256 scans were performed on each
sample for signal averaging for better signal to noise ratio. Labelled and unlabeled
lactate and glucose concentrations were measured by simple integration of the
peak(s) areas of these metabolites relative to the known concentration of DSS
(Sodium trimethylsilylpropanesulfonate as a sodium salt) that is added to each
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sample which serves as both chemical shift reference and metabolite
quantifications.
Real time-PCR
Total RNA was isolated from up to 30mg of frozen pulverized tissue using the
RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. The resulting
total RNA (1µg) was converted to cDNA using the High-Capacity RNA-to cDNA kit
(applied biosystems). Gene expression was determined by qPCR using the
following Taqman Gene Expression Assays:), Cs (Mm00466043_m1), Idh2
(Mm00612429_m1), Ogdh (Mm01179923_m1), Suclg1 (Mm00451244_m1), Sdha
(Mm01352366_m1), Fh1 (Mm01321349_m1), Mdh2 (Mm00725890_s1), Asct2
(Mm00436603_m1), Gls (Mm01257297_m1), Glud1 (Mm00492353_m1), Mct1
(Mm01306379_m1), and b-actin (Mm00607939_s1) b-actin was used as an internal
control. Data are reported as the log (base 2) of the fold change.
Immunohistochemistry
Mice were sacrificed by cervical dislocation and lungs were harvested, fixed
overnight in 4% paraformaldehyde, and paraffin embedded. Lung tissue sections
were dewaxed and rehydrated, followed by antigen retrieval in Tris-EDTA buffer (pH
9.0). Sections were then blocked using 5% goat serum and incubated with 1:100
dilution of the following antibodies overnight at 4oC: Glut1 (ProteinTech Cat. No.
21829-1-AP), Hk2 (Cell Signaling Cat. No. 2867S), and Pkm2 (Cell Signaling Cat.
No. 4053S). Sections were subsequently incubated with 1:500 dilution of HRPconjugated anti-rabbit antibody (Invitrogen Cat. No. 32260) for one hour at room
temperature. Expression was detected using DAB stain (Vector Laboratories) and
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counterstained with hematoxylin. Hematoxylin and eosin staining was performed
by the University of Louisville’s Special Procedures Laboratory within the
Department of Pathology. Imaging was performed using an Aperioscope digital
slide scanner.
Immunoblotting
Protein lysate was generated from three distinct lung tumors from both the
Kras/Rb+/+ and Kras/Rb-/- mice. 20µg of tumor or MCF-7 (positive control) protein
lysate were separated by 10% SDS-PAGE followed by transfer to PVDF
membrane. After transfer, membranes were cut between the 85kDa and 64kDa
molecular weights for simultaneous assessment of either pRb, p107, and GAPDH
using anti-RB (Cell Signaling #9309, 1:1000), p107 (ProteinTech 13354-1-AP,
1:500), and GAPDH (Millipore ABS16, 1:500) antibodies, respectively. Proteins
were visualized using 1:5000 dilution of either anti-mouse or -rabbit HRP-linked
secondary antibody and ECL prime chemiluminescent reagent (Amersham).
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism. All numerical
data are reported as mean ± SEM. Grouped analysis was performed using Oneway ANOVA with Tukey’s post-hoc comparison. For each experiment, replicates
and p values for all results are listed in their respective figure legends.
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RESULTS
Steady-state metabolomics highlights metabolic discrepencies in pRbdeficient tumors in vivo
Loss of Rb1 accelerates lung tumor progression in mutant Kras-driven lung
cancer in vivo resulting in the development of higher-grade adenocarcinomas and
decreased overall survival (131). Based on the emerging evidence that pRb
directly regulates metabolism, we hypothesized loss of Rb1 promotes a metabolic
phenotype that supports tumor progression. We have utilized a combination of
steady-state and stable-isotope labeled metabolomics to assess global changes
in metabolism resulting from pRb dysfunction in Kras-driven lung tumors in vivo
(Figure 19A).
Consistent with previous findings, loss of Rb1 significantly decreased
overall survival and increased tumor burden in this Kras-driven lung cancer model
(Figure 19B,C, 20). To identify potential pRb-dependent metabolic adaptations in
these lung tumors, we performed steady-state metabolomics analysis to analyze
the relative abundance of metabolites within major metabolic pathways.
Hierarchical clustering demonstrated distinct metabolic patterns between normal
lung, Rb1+/+, and Rb1-/- lung tumors (Figure 21). Interestingly, glucose-6phosphate, fructose-6-phsophate, glyceraldehyde-3-phosphate, and metabolites
within the pentose phosphate pathway (ribose-5-phosphate) appear to be elevated
in the Rb1-/- lung tumors. This suggests that pRb may regulate glucose utilization
in Kras-driven lung tumors as many of the qualitative changes in metabolite

66

Figure 19. Loss of Rb1 accelerates lung cancer progression in a Kras-driven
model of lung cancer. (A) Schematic of experimental design to assess the
metabolic function of pRb in Kras-driven lung tumors in vivo. For all experiments,
non-instilled KrasLSL/Rb1lox/lox mice served as normal lung controls. (B) KaplanMeier survival analysis for KrasLSL mice with wild-type (Rb1+/+) (n=53) or knockout
(Rb1-/-) (n=47) of Rb1. (C) Representative H&E staining of lung tissue from normal,
Rb1+/+, and Rb1-/- mice (representative of n=3).
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Figure 20. Confirmation of loss of Rb1 in resulting Kras-driven lung tumors.
(A) Western blot analysis of pRb and p107 in three separate lung tumors after
intratracheal instillation of Ad-Cre in either the Kras/Rb1+/+ or Kras/Rb1-/- mice.
While pRb expression is relatively low in all developing lung tumors, elevated p107
confirms loss of Rb1 in the Kras/Rb1-/- tumors as has been previously
demonstrated for this model (15). MCF-7 cell lysate was used as a positive control
for both pRb and p107 expression.
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Figure 21. Rb1 loss qualitatively alters the steady state relative abundance
of metabolites in Kras-driven lung tumors. Hierarchical clustering analysis
depicts the relative abundance of metabolites in normal lung, Rb1+/+, and Rb1-/lung tumors (n=4). Color coding indicates the row minimum or maximum for each
metabolite from least (blue) to most (red) abundant.
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abundance were observed within glycolysis or metabolic pathways originating from
glycolytic intermediates.
Loss of Rb1 enhances glycolysis in Kras-driven lung tumors
To examine differences in glucose utilization between Rb1+/+ and Rb1-/- lung
tumors, we preformed [U-13C]-glucose tracer studies. Sufficient [U-13C]-glucose
plasma enrichment was observed for both normal lung and tumor bearing mice
(Figure 22A). Utilization of ubiquitously labeled glucose results in the intracellular
generation of 13C labeling of the hexose and triose sugar intermediates within the
glycolytic pathway; resulting in fully labeled pyruvate (m+3) (Figure 23) . Pyruvate
can then be metabolized to lactate by lactate dehydrogenase (LDH),
transaminated to alanine by alanine aminotransferase (ALT), or enter TCA cycle
through pyruvate dehydrogenase (PDH) or pyruvate carboxylase (PC). It has been
previously shown that Kras-driven lung tumors display similar labeling of pyruvate
and lactate compared to adjacent lung (46). Consistent with these findings,
labeling of glycolytic intermediates from glucose carbon did not significantly differ
in Rb1+/+ tumors compared to normal lung tissue (Figure 24). Conversely, loss of
Rb1 significantly increased glucose carbon incorporation into several glycolytic
intermediates, including both pyruvate and lactate (Figure 24C,D).
We next sought to determine if the observed increase in carbon labeling of
glycolytic intermediates in Rb1-/- lung tumors was due to changes in expression of
rate-limiting

enzymes

in

Kras-driven

lung

tumors.

We

performed

immunohistochemitry analysis for glucose transporter 1 (Glut1), hexokinase 2
(Hk2), and pyruvate kinase M2 (Pkm2) in both normal and lung tumor tissue. We
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Figure 22. Rb1-/- mice exhibit increased labeled plasma glucose and lactate
when administered [U-13C]-glucose. Fractional enrichment of fully labeled
glucose (m+6) (A) and lactate (m+3) (B) in plasma from control, Rb1+/+ and Rb1-/mice. For (A, B), values represent mean +/- SEM analyzed by one-way ANOVA
with Tukey’s post-hoc comparison (normal lung n=3, Rb1+/+ n=12; Rb1-/- n=10).
Statistical significances between each group are as follows: **p<0.01.
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Figure 23. Cartoon of [U-13C]-glucose fate mapping though glycolysis.
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Figure 24. Loss of Rb1 increases glucose carbon incorporation into
glycolytic intermediates in vivo. (A-D) Fractional enrichment of m+6 labeled
glucose 6-phosphate (A), and m+3 labeled 3-phosphoglycerate (B), pyruvate (C),
and lactate (D) in normal lung, Rb1+/+, and Rb1-/- lung tumors following bolus [U13

C]-glucose injections. Values represent mean ± SEM analyzed by one-way

ANOVA with Tukey’s post-hoc comparison (normal lung n=3, Rb1+/+ n=12; Rb1-/n=10). Statistical significances between each group are as follows: *p<0.05,
**p<0.01, or ***p<0.001.

73

found that loss of Rb1 qualitatively increases Glut1, Hk2, and Pkm2 in Kras-driven
lung tumors compared to those with intact pRb and normal lung tissue (Figure
25).These results indicate that pRb enhances glycolysis, in part, via upregulation
of glycolytic enzymes in Kras-driven lung tumors in vivo.
As stated earlier, pyruvate carbon can enter the TCA cycle via two distinct
mechanisms. Pyruvate can enter the TCA cycle as acetyl-CoA generated from the
pyruvate dehydrogenase complex (PDH), or via anaplerosis in which pyruvate
enters the TCA cycle as oxaloacetate through the activity of pyruvate carboxylase
(PC) (Figure 26). PDH entry of pyruvate carbon is indicated by m+2 (1st turn)/m+4
(2nd turn) isotopologues, while PC activity is observed by m+3 isotopologue
labeling of TCA intermediates. Kras-driven lung tumors utilize pyruvate as the
primary source of TCA cycle carbon via PDH and exhibit elevated PC activity
(46,141). Consistent with these studies, we observed increased m+2 and m+4
carbon labeling in certain intermediates as well as m+3 aspartate, malate, and
fumarate in Rb1+/+ lung tumors compared to normal lung tissue (Figure 27). As
several studies have demonstrated a role for the pRb-E2F pathway in regulating
oxidative metabolism (81,96,97,142), we sought to define if loss of Rb1 further
contributes to pyruvate oxidation in Kras-driven lung tumors. Interestingly, we
observed no significant difference in both PDH or PC-mediated pyruvate carbon
entry into the TCA cycle between Rb1+/+ and Rb1-/- lung tumors in vivo (Figure
27). Moreover, loss of Rb1 does not alter gene expression of TCA cycle enzymes
(Figure 28). Taken together, analysis of [U-13C]-glucose labeling in pRb-deficient
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Figure 25. Loss of Rb1 increases expression of key glycolytic enzymes in
Kras-driven lung tumors in vivo. Immunohistochemical staining examining
glucose transporter 1 (Glut1), hexokinase 2 (Hk2), and pyruvate kinase M2 (Pkm2)
expression in normal lung, Rb1+/+, and Rb1-/- lung tumors. Images were taken
under 20x magnification and the scale bar in the lower left corner of each image
represents 200µm. Staining is representative of n=3.
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Figure 27. Loss of Rb1 does not affect pyruvate metabolism in Kras-driven
lung tumors in vivo. (A-F) Fractional enrichment of TCA metabolites in normal
lung, Rb1+/+, and Rb1-/- lung tumors (normal lung n=3, Rb1+/+ n=12; Rb1-/- n=10).
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*p<0.05 or **p<0.01.
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Figure 28. Loss of Rb1 does not affect gene expression of TCA cycle
enzymes in Kras-driven lung tumors in vivo. qPCR analysis of the TCA cycle
genes citrate synthase (Cs), isocitrate dehydrogenase 2 (Idh2), alphaketoglutarate dehydrogenase (Ogdh), succinate-CoA ligase alpha subunit
(Suclg1), succinate dehydrogenase complex, subunit a (Sdha), fumarate
hydratase 1 (Fh1), and malate dehydrogenase 2 (Mdh2), in normal lung, Rb1+/+,
and Rb1-/- lung tumors (n=4). Expression was normalized to b-actin and reported
as the log (base 2) of the fold change. Values represent mean +/- SEM analyzed
by one-way ANOVA with Tukey’s post-hoc comparison.
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lung tumors suggests loss of Rb1 enhances glycolysis without altering
mitochondrial pyruvate oxidation in vivo.
pRb does not regulate glutamine utilization in vivo
Although it has been demonstrated that Kras-driven lung tumors do not
utilize glutamine in vivo (46), loss of Rb1 has been shown to increase glutamine
utilization as a source of anaplerotic carbon for the TCA cycle in mouse embryonic
fibroblasts (MEFs) (100). As such, we sought to examine differences in glutamine
utilization between Rb1+/+ and Rb1-/- lung tumors using [U-13C,15N]-glutamine
tracer studies (Figure 29). Under three sequential bolus doses, we observed low
plasma [U-13C,

15

N]-glutamine and intracellular labeled glutamine and glutamate

for both normal lung and tumor bearing mice (Figure 30A,B). As has been
previously reported for Kras-driven lung tumors (46), we found no significant
increase in glutamine anaplerosis into TCA cycle intermediates compared to
normal lung. Interestingly, pRb-deficient tumors did not exhibit significantly
different labeling of TCA cycle intermediates compared to Kras-driven lung tumors
or normal lung tissue (Figure 30C). In addition to serving as a fuel source for the
TCA cycle, cancer cells can metabolize glutamine via reductive carboxylation to
citrate, producing acetyl-CoA via citrate lyase for lipogenesis (Figure 31A)
(64,143). We observed no significant difference in m+5 citrate generated from the
fixation of unlabeled CO2 to a-ketoglutarate (Figure 31B) (144), suggesting pRb
function does not significantly contribute to reductive carboxylation of glutamine.
Consistent with our labeling data, we did not observe any significant expression
changes in genes
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Figure 29. Cartoon of [U-13C,15N]-glutamine fate mapping through the TCA
cycle. Red circles indicate 13C and white circles indicate unlabeled 12C.

80

Plasma 13C-Glutamine

B
m+5 Fractional Enrichment

m+5 Fractional Enrichment

A
0.15

0.10

0.05

0.00

Ctrl

Rb1+/+

Rb1-/-

0.25
0.20
0.15
0.10
0.05
0.00

Glutamine

Glutamate

Tumor Bearing

m+4 Fractional Enrichment

C

Normal Lung

Rb1+/+ Tumor

Rb1-/- Tumor

0.15

0.10

0.05

0.00

Citrate

Succinate

Fumarate

Malate

Aspartate
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Fractional enrichment of fully labeled glutamine (m+5) in plasma from control,
Rb1+/+ and Rb1-/- mice. (B) Fractional enrichment of fully labeled glutamine (m+5)
and glutamate (m+5) in normal lung, Rb1+/+, and Rb1-/- lung tumors following bolus
[U-13C,15N]-glutamine injections. (C) Fractional enrichment of m+4 TCA
metabolites in normal lung, Rb1+/+, and Rb1-/- lung tumors. Values represent mean
+/- SEM analyzed by analyzed by one-way ANOVA with Tukey’s post-hoc
comparison (n=4).
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within glutamine utilization including the glutamine transporter (Asct2),
glutaminase (Gls), or glutamate dehydrogenase (Glud1) (Figure 32). Together,
our findings suggest Rb1 does not appear to influence glutamine utilization in the
context of Kras-driven lung cancer in vivo.
Loss of Rb1 does not alter lactate utilization in Kras-driven lung tumors
Recent studies have reported circulating lactate can be utilized as a TCA
cycle carbon source in both Kras-driven lung tumors in vivo as well as in NSCLC
patients (55,56). Given loss of Rb1 does not alter mitochondrial pyruvate oxidation
in animals administered labeled glucose (Figure 27), we hypothesized loss of Rb1
may influence the utilization of circulating lactate. For these studies, we developed
a labeling protocol using [U-13C]-lactate based on the method used for our [U-13C]glucose and [U-13C,15N]-glutamine tracer studies. In brief, three bolus doses of [U13

C]-lactate were administered via tail vein injection, each 15 minutes apart. Fifteen

minutes after the last injection, mice were euthanized and lung tumors or normal
lung tissue was harvested for metabolite extraction followed by 2DLC-MS/MS
analysis. Using this approach, plasma 13C-lactate was undetectable in both normal
lung and tumor bearing mice when euthanized 15 minutes after the last injection.
This is likely in part due to the high turnover rate for circulating lactate (56). To
confirm [U-13C]-lactate was being rapidly turned over, we euthanized mice at 0, 5,
or 10 minutes after the third dose of [U-13C]-lactate. When euthanized immediately,
plasma

13

C-lactate reached ~15%, then rapidly decreased by 5 and 10 minutes

(Figure 33A). Even under these conditions, we were able to observe intracellular
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Figure 32. Genetic deletion of Rb1 does not regulate genes within glutamine
utilization in vivo. qPCR analysis of glutamine transporter (Asct2), glutaminase
(Gls), and glutamate dehydrogenase (Glud1) in normal lung, Rb1+/+, and Rb1-/tumors. Expression was normalized to b-actin and reported as the log (base 2) of
the fold change. Values represent mean +/- SEM analyzed by analyzed by oneway ANOVA with Tukey’s post-hoc comparison (n=4).
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Figure 33. Rb1 deletion does not affect lactate carbon oxidation in Krasdriven lung tumors in vivo. (A) Fractional enrichment of fully labeled lactate
(m+3) in plasma from control mice following bolus [U-13C]-lactate injections. Mice
were euthanized immediately (0 minutes), 5, or 10 minutes after the last injection
(n=2 for each time point). (B) Fractional enrichment of fully labeled lactate (m+3)
and pyruvate (m+3) in normal lung, Rb1+/+, and Rb1-/- lung tumors following bolus
[U-13C]-lactate injections (n=4). Values represent mean +/- SEM analyzed by
analyzed by one-way ANOVA with Tukey’s post-hoc comparison.
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labeling of lactate-derived metabolites (Figure 34, 33B). Although tumor bearing
and normal lung mice exhibited similar levels of m+3 lactate and pyruvate (Figure
33B), we observed increased m+2 and m+3 labeling of several TCA cycle
intermediates consistent with Kras-driven lung tumors exhibiting increased lactate
utilization as a nutrient source for the TCA cycle (Figure 34, 35). However, loss of
Rb1 did not significantly alter the extent of metabolite labeling. Consistent with our
labeling data, while Kras-driven lung tumors exhibit elevated monocarboxylate
transporter 1 (MCT1: lactate import), loss of Rb1 does not further alter expression
of MCT1 (Figure 36). These data suggest that pRb does not contribute to the
control of lactate metabolism within the mitochondria of Kras-driven lung tumors in
vivo.
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DISCUSSION
In the current study, we report that loss of Rb1 in mutant Kras-driven lung
tumors leads to a metabolic shift in which pRb-deficient tumors display enhanced
glycolysis presumably via upregulation of the glucose transporter Glut1 and two
rate-limiting enzymes in glycolysis, Hk2 and Pkm2 (Figure 21). Interestingly, the
increase in labeled glycolytic intermediates in Rb1-/- tumors compared to Rb1+/+
tumors was not observed in downstream metabolites within the TCA cycle. This
was unexpected as studies have previously shown that Rb1 deletion results in
increased TCA cycle activity and mitochondrial activation in non-cancer tissues in
vivo (81,145). Conversely, other studies have reported that the pRb/E2F1 axis
directly controls PDH activity by modulating the expression of pyruvate
dehydrogenase kinase 4, suggesting loss of Rb1 function should decrease glucose
flux into the TCA cycle (96,97). Although we observed a significant increase in m+3
pyruvate labeling from glucose in pRb-deficient tumors, we found no
accompanying increase in labeling of TCA intermediates between Rb1-/- and
Rb1+/+ tumors (Figure 27); but a similar increase in labeled lactate. Additional
tracer studies to examine lactate utilization also yielded no significant difference in
labeling of TCA cycle intermediates in pRb-deficient tumors compared to those
with intact pRb.
It has recently been suggested that the decoupling of mitochondrial
oxidative phosphorylation from glycolysis provides a selective advantage to cancer
cells to sustain cell proliferation (55,56). Enhanced conversion of pyruvate to
lactate regenerates the necessary NAD+ required for elevated glycolysis to persist,
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while the use of circulating lactate for mitochondrial respiration operates in parallel
to support the energetic functions of the TCA cycle (55). Our studies support the
use of lactate as a nutrient oxidative fuel within the mitochondria of Kras-driven
tumors as has been previously reported (55). We found substantial labeling in
circulating lactate in the plasma of animals administered [U-13C]-glucose (m+3 4045%). We further observed similar labeling patterns of TCA intermediates from
mice administered either bolus [U-13C]-glucose or [U-13C]-lactate (Figure 27,35);
wherein loss of Rb1 had no significant effect. The disparity in overall labeling
enrichment in TCA intermediates between either glucose or lactate administration
is postulated to be due to differences in the levels of circulating labeled lactate
produced under these bolus dosing conditions. The use of circulating lactate as a
fuel for the TCA cycle may allow glucose to supply other anabolic pathways for cell
growth. Specifically, glucose serves as a carbon source for the synthesis of
nucleotides, amino acids, and lipids for biomass accumulation (43,57). pRb has
been reported to regulate nucleotide metabolism via its interaction with E2F family
members (86). The observed increase in aerobic glycolysis in pRb-deficient tumors
could be to sustain nucleotide synthesis; however, the labeling duration used in
our tracer studies was not sufficient to see incorporation of glucose carbon into
nucleotides, therefore additional studies will need to be performed to assess the
role of pRb in regulating nucleotide metabolism in vivo. Overall, our data indicate
that loss of Rb1 enhances glycolysis but does not influence pyruvate oxidation in
the context of Kras-driven lung tumors in vivo.

91

The role of pRb in immunity has been well described (146,147), with recent
studies demonstrating pRb inactivation recruits tumor-associated macrophages
and immunosuppressive myeloid derived suppressor cells within the tumor
microenvironment

(148).

This

was

found

to

be

due

to

increased

cytokine/chemokine secretion through altered AMP-activated protein kinase
signaling from increased fatty-acid oxidation. These studies strongly suggests a
tumor-derived metabolic contribution in regulating the immune landscape. Beyond
the effects on cell proliferation, tumor-cell derived lactate produced during aerobic
glycolysis has a profound effect on the tumor microenvironment and cancer
progression (53). Extracellular lactate has deleterious effects on infiltrating T cells
while serving as a nutrient source for immunosuppressive tumor-associated
macrophages (51-53). pRb-deficient tumors exhibit increased lactate production
from glucose (Figure 22B), yet whether this influences the immune response in
the tumor microenvironment remains unclear.
Loss of Rb1 in vitro promotes glutamine utilization via upregulation of the
glutamine transporter Asct2 and glutaminase in MEFs (100). However, this
phenomenon was not observed in vivo. pRb-deficient Kras-driven tumors do not
exhibit significant differences in glutamine carbon labeling of TCA cycle
intermediates compared to lung tumors with intact pRb, nor do they increase
expression of genes essential for glutamine utilization (Figure 30-32) . It has been
reported that while glutamine strongly contributes to oxidative metabolism in
cultured cells, circulating glutamine is not utilized as a primary fuel source for TCA
anaplerosis in vivo, particularly in Kras-driven lung tumors (46). This may explain,
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in part, the discrepancy in glutamine utilization between the MEF and transgenic
lung tumor model and suggest the metabolic functions of pRb may be dependent
on the in vivo environment of tumor cells.
Our studies demonstrate a role for pRb in regulating glycolytic metabolism
in Kras-driven lung tumors in vivo. Using both steady-state metabolomics and
stable-isotope tracer studies, we report that loss of Rb1 enhances glycolysis
without altering mitochondrial pyruvate oxidation. Additionally, our studies
demonstrate pRb does not regulate glutamine anaplerosis in vivo. Together, our
data highlights a metabolic phenotype resulting from pRb dysfunction in Krasdriven lung tumors and may support the targeting of glycolytic metabolism in
NSCLC patients with pRb-deficient tumors.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
This body of work highlights a role of pRb in mediating metabolic
reprogramming in lung cancer. Specifically, activation of pRb via treatment with
the CDK4/6 inhibitor palbociclib results in a metabolic shift in lung adenocarcinoma
cells. We found that palbociclib decreases glucose metabolism through the PPP
via inhibition of G6PD activity, while increasing dependency on glutaminolysis to
maintain basal mitochondrial function (Chapter 2). While the precise mechanism
by which palbociclib mediates its metabolic functions remain unclear, its effect on
glucose and glutamine utilization in cultured A549 NSCLC cells were observed to
be pRb-dependent as deletion of RB1 mitigated the effects of the inhibitor.
Although it has been demonstrated that glutaminolysis is not a preferential
anaplerotic carbon source for the TCA cycle in untreated or unchallenged Krasdriven lung tumors in vivo (46), glutaminase inhibition combined with standard
therapy has shown efficacy in preclinical models of lung cancer (120,149,150). It
would be beneficial to confirm these in vitro demonstrated metabolic effects in an
in vivo model under palbociclib mediated pRb manipulation. Together, our data
may support targeting CDK4/6 inhibition in combination with glutaminase inhibitors
in NSCLC patients with pRb-proficient tumors.
In other studies, we have also demonstrated that genetic depletion of Rb1
in a mutant Kras-driven mouse model of lung cancer enhances glucose
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metabolism, via upregulation of key enzymes within glycolysis, without altering
mitochondrial pyruvate oxidation (Chapter 3). One caveat to note for these studies
is the observed difference in lung tumor pathology between Kras/Rb1+/+ and
Kras/Rb1-/- mice. Kras/Rb1+/+ mice primarily develop lung adenomas, whereas loss
of Rb1 has been shown to promote greater adenocarcinoma development, which
more closely phenocopies human NSCLC (131). The metabolic adaptations that
occur during progression from lung adenoma to adenocarcinoma are largely
unknown, but we cannot rule out the possibility that this maybe a contributing factor
to the metabolic differences observed between pRb-proficient and -deficient
tumors in our model. Further technical advances will be necessary to address this
concern. To date there is no available protocol to separate adenoma from
adenocarcinoma for the metabolic analysis described in these results. Yet, many
of the metabolic changes observed in human lung cancer patients (described
below) are evident within these mouse models.
While aerobic glycolysis is a known feature of cancer cells, targeting this
pathway for therapy has proven challenging due to the cytotoxicity of many antiglycolytic agents (151). Biguanides, such as metformin and phenformin, are
common therapeutics for the treatment of type 2 diabetes and have recently been
reported to exhibit anti-cancer activity in vitro and in vivo (152-154). Specifically,
both agents have an inhibitory effect on glycolysis and oxidative metabolism. The
addition of metformin to standard therapy for lung adenocarcinoma patients
significantly improves patient outcome (155), while phenformin inhibits tumor
growth and angiogenesis in preclinical models of Kras-driven NSCLC (156). As it
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extends to this body of work, our data suggest patients with pRb-deficient lung
tumors (15-30% of NSCLC cases) may further benefit from combination therapy
that are inclusive of either metformin or phenformin treatment. This strategy can
be incorporated into future studies in defining therapeutic response of metabolic
disruptors in these mouse models in order to support the translational potential of
these findings.
Additionally, it would be of interest to expand this work into NSCLC patient
samples. There have been previous reports of metabolic changes in human
NSCLC following labeled glucose administration. Consistent with our in vivo
findings, patient lung tumors display elevated enrichment of lactate and TCA cycle
metabolites compared to adjacent lung, indicating enhanced glucose oxidation
(157,158). Interestingly, less perfused lung tumors rely heavily on glucose,
whereas highly perfused regions utilize other fuel sources such as amino acids
(158). This is primarily thought to be driven by the hypoxic environment within the
individual tumors and further underscores the heterogenous nature of human
NSCLC. However, no genotypic analysis of pRb status in these lung tumor
samples was reported. We would expect that defining the potential pRb status in
these samples would aid in correlating the patient results to those presented in our
mouse model.
Comparison of our in vitro and in vivo studies raises a conflicting question
as to why our in vitro findings of pRb dysfunction are not recapitulated in vivo and
vice versa? First, we observed changes in glutaminolysis in A549 cells under
palbociclib treatment, but manipulation of Rb1 in lung tumors in vivo did not alter
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glutamine utilization. Second, our in vivo data show that loss of Rb1 enhances
glucose utilization, but palbociclib-induced activation of pRb in vitro had no effect
on glycolysis. The most likely reason for this discrepancy lies in the metabolic
differences between cultured cells and cells found within an in vivo environment.
As stated above, solid tumors are comprised of a heterogeneous population of
cells that include malignant cancer cells, immune cells, and stromal fibroblasts, all
of which contribute to metabolic remodeling within the tumor microenvironment
(159,160). Likewise, poor vasculature in solid tumors alters nutrient and oxygen
availability, conditions which are not recapitulated in normal 2D cell culture. This
phenomenon is highly relevant to our studies, as Kras-driven lung tumor cells have
been shown to exhibit differential nutrient utilization when grown ex vivo, switching
form glucose oxidation to a reliance on glutaminolysis in culture (46). Assessment
of palbociclib treatment in this model of Kras-driven lung tumor would be beneficial
in determining whether the in vitro metabolic functions of palbociclib can be
recapitulated in vivo.
Another potential reason for the metabolic discrepancies between our in
vitro and in vivo data could be in the approach to assessing pRb function. In vitro,
we utilized an approach of drug mediated pRb re-activation in Kras-driven lung
cancer cells that harbor wild-type pRb, that is rendered inactive by
hyperphosphorylation. Conversely, our in vivo studies used a model of genetic
deletion of Rb1 that occurred at the point of tumor initiation. While the precise
mechanisms are unknown, many studies have shown that inactivation of pRb does
not phenocopy Rb1 deletion (15,161,162). This has also been demonstrated
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clinically, as inactivation of pRb confers a selective advantage to specific types of
cancer over RB1 loss. Recently, it was demonstrated that loss of RB1 in prostate
cancer is necessary for disease progression, yet pRb function remains intact in the
early stages of prostate cancer (163). Notably, the authors reported alterations in
E2F1 transcriptional networks elicited by RB1 deletion that were distinct from those
observed following phosphorylation-induced pRb inactivation. It seems feasible
that the alterations in the transcriptomes and downstream signaling pathways
between drug-induced activation of functional pRb in our in vitro studies and
complete genetic loss of Rb1 within the in vivo models may contribute to their
distinct metabolic phenotypes.
Prior studies have shown pRb can directly regulate metabolism via its
interaction with E2F (82,83,96,97,100), wherein the pRb/E2F complex regulates
the expression of target metabolic genes. However, pRb/E2F also can regulate the
expression of the components of oncogenic signaling pathways that participate in
metabolic reprogramming. Specifically, c-MYC is a known pRb/E2F target gene,
and can regulate many of the metabolic pathways we observed to be dysregulated
in our in vitro and in vivo studies such as glycolysis, nucleotide metabolism, and
glutaminolysis (164). Lastly, pRb can also drive metabolic alterations independent
of cell cycle machinery. For example, pRb can exert its effect on lipid metabolism
via interaction with SREBPs to increase expression of genes within lipogenesis
(93). Due to its wide-ranging ability to bind to over 100 proteins, many of which are
transcription factors or chromatin modifying enzymes, it would be of interest to
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characterize both the transcriptome and interactome for pRb in our models to
define precisely how pRb mediates metabolic reprogramming in lung cancer.
While more studies are needed to fully define the exact mechanisms by
which pRb exerts its control over cellular metabolism, this body of work expands
our knowledge of the metabolic phenotype resulting from pRb dysfunction in lung
cancer. It also underscores the specific metabolic perturbations defined by pRb
status that may potentially confer increased efficacy to targeted metabolic
therapies for lung cancer patients.
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Spring ‘14- Teaching Assistant
Fall ‘12

Chem-C 121/122: Elementary
Chemistry Lab 1/2
Chem-C 125: Principles of Chemistry
Lab 1
Chem-C 343: Organic Chemistry Lab 1
Chem-C 102: Elementary Chemistry 2
Chem-C 105: Principles of Chemistry 1
Chem-C 121/122: Elementary
Chemistry Lab 1/2

Leadership Experience
2016-2017

Department of Biochemistry & Molecular Genetics Student
President, University of Louisville

Affiliations
2017-present
2017-present
2016-2017

Member, American Association for Cancer Research
Member, American Society for Biochemistry and Molecular
Biology
Member, American Society of Microbiology
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